



GLOBAL COMMISSION ON
HIV and the *e*AW

RISKS, RIGHTS & HEALTH

SUPPLEMENT

JULY 2018

The content, analysis, opinions and policy recommendations contained in this publication do not necessarily reflect the views of the United Nations Development Programme.

SECRETARIAT, GLOBAL COMMISSION ON HIV AND THE LAW

UNDP, HIV and Health Group

Bureau for Policy and Programme Support

304 East 45th Street

New York, NY 10017

Email: info@hivlawcommission.org

Tel: (212) 906 6590

Web: www.hivlawcommission.org

Copyright © UNDP 2018

Images used with permission.

Graphics, Design and Printing: Phoenix

TABLE OF CONTENTS

ABBREVIATIONS	4
EXECUTIVE SUMMARY	6
INTRODUCTION: SIX YEARS ON	10
PROGRESS	13
THE LAW: ADVANCING JUSTICE AND PROTECTION.....	13
SCIENCE.....	15
POLITICS	20
STIFLING CIVIL SOCIETY.....	21
CLOSING THE FUNDING GAP	21
SURVEILLANCE, VIRTUAL AND 'INTELLIGENT'.....	23
BARRED BORDERS.....	24
PUNISHMENT	27
PEOPLE WITH HIV	27
SEX WORKERS.....	29
PEOPLE WHO USE DRUGS.....	31
PEOPLE IN PRISONS.....	31
FURTHER BEHIND	35
ADOLESCENT GIRLS AND YOUNG WOMEN.....	35
LOOKING AHEAD	38

ABBREVIATIONS

2030 Agenda	United Nations Agenda for Sustainable Development
AIDS	Acquired immune deficiency syndrome
ART	Anti-retroviral therapy
ARV	Anti-retroviral
DNA	Deoxyribonucleic acid
DR-TB	Drug-resistant tuberculosis
FOSTA	Fight Online Sex Trafficking Act
Global Fund	Global Fund to Fight AIDS, Tuberculosis and Malaria
GPS	Global Positioning System
HCB	Hepatitis B virus
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
IACHR	Inter-American Commission on Human Rights
LGBT	Lesbian, gay, bisexual and transgender
MDR-TB	Multidrug resistant tuberculosis
NGO	Non-governmental organisation
NHS	National Health Service
OST	Opioid substitution treatment
PrEP	Pre-exposure prophylaxis
R&D	Research and development
RNA	Ribonucleic acid
SARS	Severe acute respiratory syndrome
SDG	Sustainable Development Goal
SII	Self-initiated intervention
STI	Sexually transmitted infection
TB	Tuberculosis
UK	United Kingdom
UN	United Nations
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNDP	United Nations Development Programme
UNGASS	United Nations General Assembly Special Session
US	United States
WHO	World Health Organization
XDR-TB	Extensively drug-resistant tuberculosis

THE GLOBAL COMMISSION ON HIV AND THE LAW

The Global Commission on HIV and the Law is an independent body that consists of fourteen distinguished individuals who advocate on issues of human rights, HIV, public health, law and development.

Fernando Henrique Cardoso, Chair (Brazil)

Shereen El Feki, Vice-chair (Egypt)

Ana Helena Chacon Echeverria (Costa Rica)

Charles Chauvel (New Zealand)

Bience Gawanas (Namibia)

Dame Carol Kidu (Papua New Guinea)

Michael Kirby (Australia)

Barbara Lee (United States)

Stephen Lewis (Canada)

Festus Gontebayne Mogae (Botswana)

JVR Prasada Rao (India)

Sylvia Tamale (Uganda)

Jon Ungphakorn (Thailand)

Miriam Were (Kenya)

The Commission, convened by the United Nations Development Programme (UNDP) on behalf of the Joint United Nations Programme on HIV/AIDS (UNAIDS), issued its flagship publication *Risks, Rights & Health* in 2012. The Supplement does not reopen the content and recommendations of the 2012 report. Instead it adds to and amplifies the findings of the 2012 report.

ACKNOWLEDGEMENTS

The Commission expresses its gratitude for the 84 individuals who made written submissions and shared their knowledge and experience with such courage and generosity.

The Commission's work has also been ably guided by the contribution and commitment of a group of experts: Timur Abdullaev, Edwin Bernard, Chris Beyrer, Leonardo Castilho, Brian Citro, Lucica Ditiu, Chenchen Du, Richard Elliot, Carolyn Gomes, Kitty Grant, Anand Grover, Sofia Gruskin, Felicita Hikuam, Coco Jervis, Ralf Jurgens, Shannon Kowalski, Keletso Makofane, Allan Maleche, Dasha Matyushina, Oratile Moseki, Steave Nemande, Kevin Osborne, Amitrajit Saha, Ehab Salah, Rebecca Schleifer, Boemo Sekgoma, Tim Sladden, Tracy Swan, MaryAnn Torres and Georgia White.

The Commission warmly acknowledges the support of its Secretariat under the leadership of Mandeep Dhaliwal (Director: HIV and Health, UNDP) and Tenu Avafia (Team Leader: Rights, Law and Access, UNDP). The Commission is grateful for the hard work of Secretariat staff: Kene Esom, Firass Halawi, Boyan Konstantinov, Justus Einfeld, Stefan Newton, Roy Small, Ludo Bok, Vera Hakim, and Jelena Kucelin. The Commission also wishes to express its appreciation for Judith Levine, the lead writer, and the staff of Global Health Strategies for their communications work.

EXECUTIVE SUMMARY

In 2012, the Global Commission on HIV and the Law called on countries to outlaw discrimination, repeal punitive laws and enact protective laws to promote public health and human rights for effective HIV responses. Today more than 89 countries have taken action to repeal or reform laws: some have repealed laws criminalizing HIV, same-sex relations, and drug possession, and others have enacted laws advancing reproductive rights, sex education, and the human rights of people living with or at risk from HIV.

In 2015, at the United Nations (UN) General Assembly, countries unanimously adopted the 2030 Agenda for Sustainable Development (2030 Agenda). The 2030 Agenda, grounded in human rights principles, established an ambitious target to end the epidemics of AIDS and tuberculosis (TB). The 2030 Agenda made a bold pledge to leave no one behind.

This Supplement highlights developments since 2012 in science, technology, law, geopolitics, and funding that affect people living with or at risk from HIV and its co-infections. The recommendations add to and amplify those of the Commission's 2012 report *Risks, Rights & Health*, which remain as relevant as they were six years ago.

FINDINGS

HIV treatment increased but AIDS is not over; other epidemics loom. Of the estimated 36.7 million people living with HIV, 20.9 million were receiving anti-retroviral therapy (ART) by mid-2017, almost triple the number in 2010. Declines in new HIV infections among adults are far too slow, threatening further progress towards the end of the AIDS epidemic. HIV continues to be a disease of the vulnerable, marginalised and criminalised—gay men and other men who have sex with men, transgender people, people who use drugs, sex workers, prisoners, migrants and the sexual partners of these populations. Key populations and their sexual partners account for 47% of new HIV infections in 2017. Adolescent girls and young women aged 15-24 suffered 20 percent of all new HIV infections.

Progress is also dogged by epidemic **viral hepatitis** and **tuberculosis**, co-infections that complicate and threaten the lives of people with HIV, and vice-versa. About 2.8 million people living with HIV are co-infected with hepatitis C virus (HCV) and 2.6 million with hepatitis B virus (HBV). Globally, more than 13 percent of people with TB tested for HIV received positive results, and TB is the leading cause of HIV-related deaths. New medications can cure HCV within two to three months with minor side-effects. More countries are using legal and policy remedies to bring down high costs of medicines to increase treatment access. But lack of investment in research and development (R&D) of new diagnostics and tolerable treatments for TB, a disease of the poor, has made cure of this ancient disease elusive for far too many people.

Science leapt forward. Three major studies have proved that HIV-positive people with viral loads sufficiently suppressed by ART pose a zero risk of transmission. At the same time, pre-exposure prophylaxis (PrEP), taken as prescribed, protects the uninfected from contracting HIV in almost all instances. These facts have helped lawyers defend against prosecutions for HIV exposure and transmission based on the misconception that HIV is a “deadly weapon.” Still, advocates are concerned about the misuse of DNA analyses to infer transmission and the use of artificial intelligence to identify HIV “suspects.”

Online markets for medications and “self-initiated interventions” such as readily available HIV tests are enabling people to care for their own health reliably and without stigma, even where products are sometimes inaccessible or illegal in the countries where these people reside. But efficacy, safety, and privacy are concerns, and effective regulation is needed.

Civic space shrank. Between 2012 and 2015, more than 60 countries drafted or enacted laws, or stepped up enforcement of older ones, to outlaw, harass, vilify, attack, or bankrupt civil society organisations and international

aid groups that help them. Lesbian, gay, bisexual and transgender (LGBT) people have been targeted with special brutality, including through “anti-homosexuality propaganda” laws. A virtual public square, the Internet, also became a site of corporate exploitation, government surveillance, content manipulation, and incitement to violence against “undesirables.”

Donor funding dropped. In 2015, donor funding for HIV fell by 13 percent. “Middle-income countries” now shoulder more than half the burden for financing HIV responses. Funding gaps extend to TB and viral hepatitis as well. New economic realities require financial innovation. But there is no substitute for solidarity between the wealthy and the poor - an approach that has yielded significant progress in the global AIDS response. Latest data shows no significant new commitments from donors and donor government funding for HIV decreased in 2017.

Criminalisation persisted. As of July 2018, 68 countries criminalise HIV non-disclosure, exposure or transmission, or allow the use of HIV status to enhance charges or sentences on conviction. HIV prosecutions have been reported in 69 countries. Belarus, Canada, Russia and the United States lead in the number of prosecutions. In some countries TB patients have been criminalised for not adhering to and completing treatment.

Anti-sex work laws remain problematic. Several countries have adopted the “end-demand” model of arresting sex workers’ clients rather than the workers themselves. With the noble intent of ending human trafficking, in 2018 the United States (US) passed legislation allowing legal action against websites that host ads for paid sexual services. Sex workers say that such laws erode their safety, control and earnings. New research concludes that decriminalisation of adult consensual sex work could significantly reduce HIV infection among sex workers.

The war on drugs goes on. Some countries decriminalised possession of small quantities of drugs. Still, depending on the locality, people who use drugs often remain excluded from HIV, TB, and hepatitis treatments, or are subjected to coerced or confined TB treatment. Imprisoned patients are lost to follow up. Mothers who use drugs were especially vulnerable, locked up while pregnant to compel recovery and threatened with loss of child custody if they failed to pursue treatment after birth.

Borders tightened. With the 258 million migrants, including 28.5 million refugees and asylum seekers, some countries adopted restrictive immigration policies, including visa denials, screenings, and deportation based on health status.


Women and girls left further behind. Criminalisation, discrimination and violence continue to undermine women’s and girls’ ability to protect their health and realise their rights. Sexual and reproductive health and HIV are closely linked. Legal and human rights barriers continue to impede access to sexual and reproductive health services and increase women’s and girls’ vulnerability and risk. Healthcare providers in over 70 jurisdictions have used conscientious objection to deny care to women and girls. The 2017 US “global gag rule” is compounding risk and increasing vulnerability.

RECOMMENDATIONS

In addition to the recommendations made in the Commission’s 2012 report *Risks, Rights & Health*, to ensure effective, sustainable health responses consistent with universal human rights obligations, the following measures must be adopted as a matter of urgency:

1. Governments must prohibit in law all forms of discrimination against people living with and vulnerable to HIV, TB or viral hepatitis. Governments must take steps to repeal or amend any laws or policies that discriminate against people based on HIV, TB or hepatitis status.
2. Governments and other funders of biomedical R&D must urgently increase investments in R&D of new health technologies, including diagnostics, medicines and vaccines for HIV, TB and viral hepatitis. Governments and public funders of R&D must consider and implement alternative policies such as tax incentives and prize awards to encourage R&D investment by the private sector in neglected diseases such as TB.
3. Governments must ensure that everyone living with or at risk of acquiring HIV, TB, or viral hepatitis has affordable access to the most effective, high-quality health technologies, including diagnostics, medicines and vaccines for HIV, TB and viral hepatitis.

4. Governments must establish legal protections to safeguard the privacy and confidentiality of social media users, digital health technologies, online healthcare records, electronic medical records and communications with healthcare providers. Governments must protect sensitive health information such as HIV status or hepatitis or tuberculosis infection against unjustifiable access and impose strong penalties on those that violate users' rights.
5. Governments must stop the use of laws restricting the registration and operation of civil society organisations or their sources of funding to curtail their activities. Where any such laws have been enacted, countries must repeal or refrain from enforcing them.
6. Governments must enact laws that provide an enabling environment for civil society organisations to operate, including those providing services to populations living with or affected by HIV, TB or viral hepatitis.
7. Governments must refrain from enacting laws that require non-heterosexual sexual orientations to be portrayed as inherently inferior.
8. Donors and governments must sustain support to civil society programmes and legal reform efforts aimed at defending and promoting the human rights of people living with HIV, TB or viral hepatitis, particularly in marginalised groups.
9. Assuming that the transition from international to domestic funding continues, donors must ensure that they do not desert countries with inadequate resources for effective responses to HIV and its co-infections.
10. Governments must assume greater responsibility for financing their HIV, TB and hepatitis responses. This includes ensuring sufficient investment in human rights programmes for law reform and access to justice.
11. Governments and the private sector must adjust their policies and subventions for universal health coverage to focus on the rights of individuals to access the highest attainable standard of health. They must not derogate from individual rights provided in international human rights law by reference to economic classifications of national wealth that result in derogations from these human rights.
12. Governments must prohibit the non-consensual use by law enforcement or private entities of digitally-collected or stored private information, especially data related to sexual and reproductive health. Such data must not be used for discriminatory purposes or for commercial surveillance, profiling or targeting, except as provided by law, with the informed consent of the subjects and in circumstances consistent with universal human rights.
13. Governments must stop the censorship and restriction on Internet access and communication except where provided by law that is consistent with universal human rights law. Governments must facilitate the use of Internet and evidence-based information, education and communications platforms to promote access to health and rights information and services.
14. Governments must refrain from denying entry, restricting their travel within national borders or deporting people living with HIV, TB or viral hepatitis based on their positive status. Governments must repeal such laws where they exist.
15. Governments must not mandate universal HIV, TB, or viral hepatitis testing of foreign nationals. If such laws or policies exist, they should be repealed or abolished. Any requirements to undergo such tests should only occur where provided for by law, for proper purposes consistent with universal human rights law.
16. Governments must provide migrants, including asylum seekers or refugee applicants, access to the full range of health services including for HIV, TB and viral hepatitis regardless of immigration status. Governments must provide this standard of care in detention and confinement settings.
17. Governments must amend laws and policies that deter health seeking among migrant populations, such as requirements to show national identification documents, residence cards, or to only receive treatment in their home region or country.

- 
18. In countries where HIV criminalisation laws still exist, courts must require proof, to the applicable criminal law standard, of intent to transmit HIV. The intent to transmit HIV cannot be presumed or derived solely from knowledge on the part of the accused of positive HIV status and/or non-disclosure of that status; from engaging in unprotected sex; by having a baby without taking steps to prevent mother-to-child transmission of HIV; or by sharing drug injection equipment.
 19. Governments must ensure that, where an HIV-specific law has been repealed, there is a restriction on the application of any general laws to the same effect either for HIV or TB.
 20. Governments must prohibit the prosecution—under HIV-specific statutes, drug laws, or child abuse and neglect laws—of women living with HIV for choices they make during and after pregnancy, including about breastfeeding children.
 21. Whenever HIV arises in the context of a criminal case, police, lawyers, judges and where applicable, juries, must be informed by the best available scientific evidence concerning the benefits and consequences of appropriate therapy, and the individual and community advantages of maintaining such therapy.
 22. Governments must ensure that HIV status is not used as such to justify pre-trial detention, segregation in detention or prison, or harsher or more stringent sentences or conditions of parole or probation following release from custody.
 23. Governments must refrain from adopting laws based on the “end-demand” model of sex work control and repeal such laws where they exist.
 24. Governments must not pass laws prohibiting, penalising, or enabling legal action against Internet site owners or other media interests that accept advertisements for sex work. If such laws have been adopted, the governments concerned must repeal them.
 25. Governments must not employ coercive methods or confinement during treatment of persons who use drugs nor detain or imprison anyone for failure to take up, adhere to or successfully complete HIV, TB or viral hepatitis therapy or drug dependence treatment.
 26. Governments must repeal laws or regulations that mandate total abstinence from drug use as a pre-condition for accessing treatment for HIV, TB or viral hepatitis.
 27. Governments must make every effort to ensure that incarceration is a last resort for drug use and drug-dependence offences and should instead promote alternatives to incarceration for drug use and drug-dependence offences.
 28. Governments must adopt legal protections to prevent discrimination against people who use drugs.
 29. Governments must adopt and enforce laws that protect and promote sexual and reproductive health and rights. Governments must remove legal barriers to accessing the full range of sexual and reproductive health services.
 30. Governments must limit the use of “conscientious objection” in healthcare where the health and lives of others are at risk as a consequence.

INTRODUCTION: SIX YEARS ON...

Six years since its publication, the report of the Global Commission on HIV and the Law, *Risks, Rights & Health*, remains relevant. A legal environment that respects, protects and fulfils human rights, and promotes overall health and well-being, is an efficient and effective means of reducing the risks and the toll of disease on people and resources.¹ Laws alone are insufficient to achieve these objectives, but bad laws are a serious impediment to health and good laws can contribute to good health.

The overarching recommendations of the Global Commission on HIV and the Law are as urgent as ever:

- Outlaw discrimination and violence against people who are living with and vulnerable to HIV;
- Repeal laws that control and punish people who are living with and vulnerable to HIV; and
- Adopt laws and policies that enable effective prevention, treatment, and care and uphold human rights.

These principles find strong endorsement in the 2030 Agenda, grounded in the human rights principles of the dignity of the individual, equality, and non-discrimination.² Sustainable Development Goal (SDG) 16 envisions "... peaceful and inclusive societies...[and] access to justice for all...". SDG 3 commits the international community to "ensure healthy lives and promote well-being for all at all ages".³ The targets of SDG 3 include:

- Ending the epidemics of AIDS, TB, and other diseases;
- Combatting hepatitis;
- Ensuring universal access to sexual and reproductive healthcare services;
- Supporting research and development of vaccines and medicines especially for diseases that primarily affect developing countries; and
- Providing access to affordable essential medicines and vaccines.⁴

The 2030 Agenda boldly pledges to leave no one behind, and to reach the furthest behind first.⁵

Several other global agreements, declarations and strategies echo the messages of the Commission's 2012 report.⁶ Such declarations and blueprints are crucial, as are the legal and policy reforms proposed to realise them. However, such reforms take time. In the last six years, UNDP, in partnership with other UN entities, civil society and development partners, has supported governments in 89 countries to advance the recommendations of the Global Commission on HIV and the Law. Taking up one of the Commission's most pressing recommendations, in 2015, then-UN Secretary General Ban Ki-moon established the High-Level Panel on Access to Medicines.⁷ This panel made recommendations for addressing incoherencies and longstanding misalignments between international human rights, trade, intellectual property, and the public health objectives of the 2030 Agenda and the SDGs.⁸

PROGRESS

To people living with and vulnerable to HIV, the past half-decade has delivered remarkable advances. In 2012, the World Health Organization (WHO) issued guidelines for the use of pre-exposure prophylaxis (PrEP), a combination of anti-retroviral medicines that significantly reduces the risk of HIV transmission.⁹ By 2017, three major studies had provided robust evidence that ART can suppress a person's HIV viral load to undetectable levels. The statistical risk of HIV transmission from a person living with HIV whose viral load is suppressed is zero.¹⁰ The tools for preventing and treating HIV are better than ever.¹¹ However, it is not yet time to declare victory in the struggle to end AIDS.

Access to HIV treatment has greatly expanded. Of the estimated 36.7 million people worldwide living with HIV, 20.9 million were receiving ART by mid-2017, almost triple the number in 2010. New HIV infections are down 11 percent among adults and 47 percent among children.¹² New medications can cure HCV, an HIV co-infection, in almost all cases, within two to three months, with minimal side effects.¹³

The legal picture is brighter in some respects. Thanks in large part to unceasing pressure from civil society, many governments have updated or repealed some of the worst laws criminalising HIV exposure, transmission, and non-disclosure, and the possession and use of illicit drugs.¹⁴ Every year more legal codes remove the stigma of criminalisation for LGBT people, enact positive protections against discrimination, and empower the formation of legally-recognised relationships and families.¹⁵

REGRESSION

Despite these encouraging advances, this half-decade has also witnessed several examples of stagnation and even backsliding on progress for those living with HIV and its co-infections. While new HIV infections decline, the number of people living with HIV has risen steadily: There are an estimated 2.7 million more people today living with HIV than there were in 2010.¹⁶ Members of marginalised populations – gay men and other men who have sex with men, people who use drugs, sex workers, transgender people, prisoners, and their sexual partners – accounted for 47 percent of new infections in 2017.¹⁷ Viral hepatitis and TB, the leading co-infections for people living with HIV, are treatable, yet millions are not being treated. The new treatments for HCV are too expensive for millions to access.¹⁸ Governments, funders and biomedical companies have invested little in developing diagnostics, vaccines, or medicines for TB, a disease of poverty and inequality, making the cure of this ancient disease elusive for far too many people.

Highly lamentable is the failure to stop infection and death among young people. Adolescent girls and young women aged 15-24 account for 20 percent of all new HIV infections, despite accounting for just 11 percent of the population.¹⁹

These marginalised populations, in many places, are under attack by the very governments that are obliged to protect their health and rights. With alarming vigour, many governments are rescinding women's reproductive rights, persecuting LGBT people, sex workers, and people who use drugs, and stifling the civil society groups that provide services, hold governments to account and mobilize calls for justice. These wrongs are happening despite the clear evidence presented in the report of the Global Commission on HIV and the Law that outreach to and collaboration with key populations have positive benefits for reversing the HIV epidemic.

Persecution, along with economic hardship and violent conflict are among the causes driving an unprecedented number of people from their homes: 258 million migrants, including 28.5 million refugees and asylum seekers, are now in search of safety and hope.²⁰ With uncertain access to food, clean water and health services, they are vulnerable to illness and violence, including gender-based and sexual violence.²¹ This massive displacement, which should trigger a greater outpouring of aid and solidarity, instead receives insufficient attention in the news-cycle and the political discourse.²²

In another blow to global solidarity, donor funding for AIDS fell by 13 percent in 2015, the same year that countries adopted the 2030 Agenda and pledged to leave no one behind.²³ More than half the financial burden of the HIV epidemic in the so-called low- and middle-income countries now rests on domestic governments.²⁴ In reality, some of these countries are the least able to afford such expenditures and many will fail to reach the SDG targets.

THE FUTURE

This Supplement builds on the 2012 report by highlighting recent developments in HIV-related science and the legal environment, both for better and for worse. It links these to the evolving global political and funding situation. The Supplement particularly highlights the worrying medical, social, and fiscal impact of HIV's close companions, TB and viral hepatitis. The need to focus on HIV, TB and viral hepatitis in this Supplement is based on a greater understanding of the extent to which these diseases interact. The risk of acquiring any of the three diseases creates reciprocal, interdependent effects²⁵ and the populations living with and vulnerable to these diseases often suffer from stigma, discrimination and punitive laws, policies and practices. In this Supplement, the Commission offers further and more detailed recommendations regarding the law in light of the new realities. Finally, as in 2012, the Supplement amplifies the voices of people living with and vulnerable to HIV, and now, those living with TB and viral hepatitis, as well as their families, sexual partners and communities. It recognises and highlights the work of those dedicated to making human rights declarations and public health strategies an everyday reality. It is for these individuals and their dependants that the bold vision for global human rights, justice and development, set forth in the 2030 Agenda and in the original report of the Global Commission on HIV and the Law, must be achieved.

Snapshot of progress (2012-2018)



Laws

Some countries have reformed their laws to promote more evidence- and rights-based responses to HIV.

- HIV criminalisation laws have been removed in a number of countries – for example, Ghana, Greece, Honduras, Kenya, Malawi, Mongolia, Switzerland, Tajikistan, Venezuela, Zimbabwe, and two states in the US.
- Other countries including Belize, Mauritius, Mozambique, Nauru, Palau, São Tomé and Príncipe, Seychelles and Trinidad and Tobago have decriminalised adult, consensual same-sex relations.
- A number of countries have decriminalised some aspects of drug possession or use – for example, Canada, Colombia, Jamaica, Norway and Uruguay have decriminalised possession of small amounts of cannabis, and Jamaica expunged the criminal records of low-level drug offenders.
- Some countries have taken important steps to improve access to sexual and reproductive healthcare services for young people – for example, women and girls led successful advocacy in Costa Rica, Ecuador, El Salvador and Guatemala for laws recognising the right to comprehensive sexuality education.
- Several countries have taken steps to enact or reform laws to protect women from violence - for example, Tunisia recently passed a law to end violence against women in public and private life and Jordan and Lebanon have closed “marry-your-rapist” loopholes in their legal codes.



Civil society

Civil society continues to play a vital role in the fight for dignity and justice, leading efforts on legal awareness, legal aid, strategic litigation, law reform and advocacy. For example, the Regional HIV Legal Network provides people with HIV and marginalised groups access to quality free legal aid in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia and Ukraine. The Middle East Network on Legal Aid, a civil society coalition, provides legal aid services for people living with HIV and marginalised groups in a number of countries. Strategic litigation led by civil society, in several countries such as Belize, Botswana, India, Kenya, Malawi, Uganda and Ukraine, has advanced the rights of those most vulnerable to HIV.



Funding

Scaling up human rights programmes such as law reform and access to justice takes time and requires substantial investment. The 2017-2022 strategy of the Global Fund to Fight AIDS, TB and Malaria: Investing to End the Epidemics has a high-level objective on human rights which calls for scaling up human rights programmes and interventions to support women and girls, such as those to advance sexual and reproductive health and rights.

THE LAW: ADVANCING JUSTICE AND PROTECTION



In the past six years dozens of states and jurisdictions have taken steps, informed by evidence and human rights obligations, towards ending AIDS. These include:

- Decriminalising HIV exposure, non-disclosure and unintentional transmission;
- Decriminalising consensual same-sex relations;
- Legally recognising same-sex relationships;
- Decriminalising or legalising possession and personal use of identified illicit drugs;
- Making reproductive and sexual healthcare services more accessible to adolescents, in part by lowering the age of consent; and
- Tackling harmful cultural practices such as child, early, and forced marriage.

In short, a range of countries have ceased punishing people who are vulnerable to HIV, and instead have begun to use the law to protect their rights to life, health, bodily autonomy, equality and privacy.³⁶

Our engagement with the parliament committees, especially the committee on HIV and AIDS, has made it possible for our organisation to attain the objectives in the work that we are involved in, that of ensuring access to treatment for all as part and parcel of bringing change and development to Malawi.

Malawi Network of People Living with HIV/AIDS

Civil society and organisations of people living with and affected by HIV have been on the frontlines, leading advancements in justice and protection. For example:

- Serbia's Centre for the Empowerment of Youth has investigated claims of discrimination by dentists against people living with HIV.³⁷
- LGBT groups in Belize have collaborated to advance the rights of their members through the courts.³⁸
- While fighting for repeal of punitive laws, the sex worker organisation Alliance of Women Fighting for Change brought together police, health providers, and sex workers to find ways to work around repressive laws. In Uganda, one in three sex workers are HIV-positive.³⁹
- In 2012, the Law Enforcement and HIV Network published a Statement of Support for harm reduction approaches, signed by over 10,000 police and police agencies around the world.⁴⁰
- In May 2018, Irish citizens voted to recognise and uphold women's right to abortion in law, by a two-to-one majority, after achieving a similar result in May 2015 to confer equal legal recognition on same-sex relationships.

Courts leading the way

MALAWI: EL v Republic (2016)³¹

A woman living with HIV and on ART was convicted under Section 192 of the Penal Code for an “unlawful, negligent or reckless act that is likely to spread a disease dangerous to life.” Her crime: breastfeeding a child while living with HIV. Although the child did not contract HIV, EL was charged nonetheless. Without a lawyer, EL pleaded guilty and was sentenced to nine months’ imprisonment. Later with legal representation, EL appealed to the High Court. She relied on evidence drawn from Malawi’s HIV policy and the WHO and UNICEF Guidelines on HIV and Infant Feeding. These and the fact that she was on ART established the infinitesimal chance of her transmitting HIV to the child. The ruling illustrated the importance of grounding judicial decisions in scientific evidence and affirmed the law’s function in protecting people living with HIV from “the unjust consequences of public panic.”

INDIA: Kaushal Kishore Tripathi v Lal Ram Sarup TB Hospital and others (2016)³²

The petitioner was diagnosed with TB in 2013. As the drugs prescribed failed to slow the course of the young woman’s illness, her family travelled 660 miles to access bedaquiline – a new treatment for drug-resistant TB (DR-TB), at a government hospital in New Delhi. The hospital denied the petitioner access because she was not a New Delhi resident. The young woman had extensively drug-resistant TB (XDR-TB) confirmed by a drug susceptibility test (DST) in 2014, as well as extensive clinical history of treatment failure. The hospital wanted another DST done in 2016 before it would consider providing bedaquiline. Bedaquiline is only available in a handful of Indian cities and then only for the small number of patients with laboratory evidence of XDR-TB. The family based her claim on the grounds that the woman had a right to life-saving treatment, claiming that her medical history indicated a likelihood of XDR-TB. The Court ordered that bedaquiline be administered to the petitioner and also required the national drug regulatory agency to process her application for another drug-resistant TB drug, delamanid, within 24 hours. The petition also led the Government of India to remove the residency criterion for bedaquiline eligibility.

CANADA: Attorney General of Canada v Bedford and others (2013)³³

The applicants, three advocates for sex workers’ rights, argued that Canada’s prostitution laws were unconstitutional. Even though prostitution, as such, was legal under Canadian law, the Criminal Code outlawed a number of related acts, such as operating a “bawdy house”, using public communication for the purposes of prostitution, and living off its gains. The applicants argued that such laws deprived sex workers of their right to security of work by forcing them to work secretly. In 2012, Ontario’s Court of Appeal ruled that some of the law’s prohibitions violated the Canadian Charter of Rights and Freedoms and were unconstitutional. In 2013, the Supreme Court of Canada ruled unanimously that all such restrictions were unconstitutional and directed Parliament to amend the laws in accordance with its ruling. The Canadian Government propounded the amended law on 6 November 2014 in compliance with the deadline given by the Supreme Court.

BOTSWANA: ND v Attorney General of Botswana and others (2017)³⁴

A transgender man petitioned the Court to compel the Registrar of the National Registration of Botswana to issue new identity documents to reflect his male gender. The High Court ordered the Registrar to change the gender marker on the document from female to male. “Gender identity constitutes the core of one’s sense of being and is an integral (part) of a person’s identity,” the Court observed. “Legal recognition of the applicant’s gender identity is therefore part of the [fundamental] right to dignity and freedom to express himself in a manner he feels ... comfortable with.” The Court declared that lack of such recognition in Botswana exposed transgender persons to discrimination, stigma, and harassment. It noted the distress that the applicant experienced when required to explain intimate details of his life to strangers whenever he sought routine services. That ordeal amounted to a violation of his right to privacy, which the state could prevent or minimise by allowing him to change the gender stated on his identity document.

TRINIDAD & TOBAGO: Jason Jones v Attorney General of Trinidad and Tobago (2017)³⁵

The claimant petitioned the court to strike down Sections 13 and 16 of the Sexual Offence Act and by so doing to decriminalise consensual sexual relations between persons of the same sex. Responding to the State’s argument that the law was needed to maintain traditional family values, the court asked, “What is a traditional family? If it is limited to a mother, father and children, then ... the rationale for keeping that template is no longer sufficiently important as the rationale for denying the claimant’s fundamental rights. For example, single-parent families are becoming the norm, which is unsettling to many traditionalists despite its reality.” In ruling the two sections of the Act unconstitutional, the court recognised that “the beliefs of some, by definition, [are] not the belief of all”. It held that the Constitution of the Republic of Trinidad and Tobago protected all.

SCIENCE



When the Commission's report was published in 2012, HIV had long ceased to be a deadly disease. Instead, with ART, HIV had been transformed to a chronic condition with which people could live long, fulfilling lives. With highly active ART, an HIV-positive mother could give birth and nurse without passing the virus on to her baby.³⁶ Today scientists know and speak with increasing authority on the role of ART as HIV prevention.³⁷

TREATMENT AS PREVENTION

Three major studies prove decisively that ART can suppress a person's HIV viral load to less-than-measurable levels, bringing sexual transmission rates for HIV statistically to zero.³⁸ The proved effects of ART have transformed the daily lives of people living with HIV. This is giving rise to new and different public health campaigns, policies and strategies worldwide.³⁹ This fact can and must change the law and its enforcement.

PrEP

In 2012, WHO first published guidance on the use of oral PrEP for sero-discordant couples, transgender women and men who have sex with men.⁴⁰ PrEP, has been shown to be safe and effective at preventing HIV, when taken as prescribed.⁴¹ Today, over 40 countries are offering PrEP to those most vulnerable to contracting HIV.⁴² Costs are a concern, for rich as well as poorer countries.⁴³ However, even at the highest prices, the economic considerations strongly support the public health case: the costs of HIV

Scientists never like to use the word never. But I think in this case we can say that the risk of transmission from an HIV-positive person who takes treatment and has an undetectable viral load may be so low as to be unmeasurable, and that's equivalent to saying they are non-infectious. It's an unusual situation when the overwhelming evidence base in science allows us to be confident that what we are saying is fact.


Anthony Fauci, Director, National Institute for Allergies & Infectious Diseases, United States

dwarf those of providing PrEP to everyone at high risk.⁴⁴ This realisation was at the heart of the ruling of the Court of Appeal of England and Wales in the United Kingdom confirming that the power to commission and fund PrEP lies with the competence of the National Health Service (NHS) England.⁴⁵ However, PrEP is still not available in most parts of the world.⁴⁶

According to WHO, PrEP is an additional HIV prevention choice and should not replace or undermine other effective, well-established HIV prevention interventions such as condom use.⁴⁷ The consistent use of latex condoms is still a highly effective means of preventing the spread of HIV and other sexually transmitted infections (STIs). In fact, an increase in potentially risky sex without condoms, in communities where PrEP is more widely used, has worrying ramifications for the transmission of other diseases.⁴⁸ While these concerns make the case for complementary efforts on STI prevention, they do not justify not providing PrEP to people who are at high risk of acquiring HIV.

The Partner Study found that daily PrEP use among sero-discordant couples was even more effective than we thought.

Nelly Mugo, Principal Research Scientist, Kenya Medical Research Institute



Viral suppression from ART prevents HIV transmission

Source: Rodger A. et al (2016), *Sexual activity without condoms and risks of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy* JAMA. 2016;316(2):171–181. doi:10.1001/jama.2016.5148 and and AVERT, *Treatment as prevention (TasP) for HIV*, [2017]. Available at <https://www.avert.org/professionals/hiv-programming/prevention/treatment-as-prevention>

CO-INFECTIONS

A potentially optimistic outlook for HIV is clouded by two other epidemic illnesses: TB and viral hepatitis. People living with HIV are disproportionately susceptible to these co-infections and vice-versa.⁴⁹ These co-infections tax fragile, over-extended health systems. They threaten already limited health budgets.⁵⁰

VIRAL HEPATITIS

Hepatitis is a virus that causes a chronic and potentially fatal liver disease. Globally, an estimated 240 million people are living with HBV and 130-150 million with HCV. There are 8 million new infections yearly between the two.⁵¹ Experts warn that without a more urgent, comprehensive response, little progress will be made in reducing these numbers in the next half-century.⁵² About 2.8 million people living with HIV are co-infected with HCV and 2.6 million with HBV.⁵³ Viral hepatitis progresses more rapidly to liver damage in people living with HIV, while also undermining the management of the HIV infection.⁵⁴ Globally viral hepatitis results in an estimated 1.4 million deaths a year from complications including cirrhosis, liver cancer, and liver failure—a comparable number to the deaths caused by TB and HIV.⁵⁵ The number of people dying from viral hepatitis is climbing.⁵⁶

In high-prevalence countries, the main mode of transmission of HBV is from mother-to-child.⁵⁷ The most

common way to contract HCV is through sharing needles from injecting drugs—although the virus can also spread through non-sterilized medical and dental tools as well as blood products, tattoo needles, and shared razors.⁵⁸ Of the estimated 12 million people worldwide who inject drugs,⁵⁹ 67 percent have HCV.⁶⁰ “Chemsex”—the use of crystallised methamphetamine and other amphetamine stimulants to intensify the sexual experience—has also been linked to risky behaviour such as sex without condoms, increasing rates of HIV and HCV transmission.⁶¹

Like HIV, both HBV and HCV can be prevented through safer sex, ensuring safe blood products and harm reduction, including the provision of clean needles for people who inject drugs.⁶² HBV is treatable, usually with lifelong medication.⁶³

Research for the treatment and cure of HCV, a disease of both rich and poor, has been well-funded resulting in an effective treatment for HCV. Direct acting antivirals, such as sofosbuvir, daclatasvir and lepidasvir, can cure more than 95 percent of people with HCV in two to three months, often with minor side effects. However, licenses negotiated between patent-holders to other manufacturers have resulted in widely varying prices for these drugs.⁶⁴ Competition may reduce prices in some instances, but excessive prices where patent rights guarantee monopolies can drain the budgets of countries excluded from voluntary

licensing agreements or from pricing discounts. Even richer countries are struggling: Canada, Italy and the US were rationing treatment for HCV at various stages, due to the high costs of medication or advanced progression of HCV.⁶⁵

When prices fall, more people are able to access treatment. Egypt, the country hardest hit by HCV, negotiated a 99 percent discount on sofosbuvir in 2014.⁶⁶ When it set up an Internet registration site, 100,000 people signed up for treatment the first day. Patients began flying in from other countries. A generic version, recently launched and manufactured in Egypt, brought the price to about \$82 per course - or as little as a dollar a day.⁶⁷ This was the price at which Yusuf Hamied, Managing Director of Cipla, an Indian generic manufacturer, committed to providing ART in 2001, dramatically altering the course of the global HIV response. In 2015, Portugal instituted universal access to HCV treatment, followed by France in 2016.⁶⁸ When Australia offered discounted HCV treatment through the national Pharmaceutical Benefits Scheme, the number of people starting treatment jumped from 7,296 in 2015 to 26,360 in less than a year. It continues to rise rapidly.⁶⁹

TUBERCULOSIS

Tuberculosis, an ancient infection, is one of the world's top 10 causes of death.⁷⁰ It is, above all, a disease of poverty and inequality. It disproportionately affects those who are malnourished or living in sub-standard conditions, as well as people who use drugs or who are prisoners. One-fourth of the world's population carries the TB bacterium.⁷¹ Without immediate action, an estimated 28 million people will die of TB by 2030.⁷² People living with HIV are 21 to 34 times more likely to develop active TB compared to those without HIV, with the speed of progression from latent TB to active TB shrinking from years to weeks.⁷³ Thirty-seven percent of deaths in people living with HIV are due to TB,⁷⁴ making TB a major cause of AIDS-related deaths.

Largely because TB afflicts the poor almost exclusively, investment in research and development of effective diagnostics, medicines and vaccines is under-resourced. In the high disease-burden countries of the developing world, access to advanced, expensive diagnostics, including rapid molecular tests, remains low. National programmes rely on old and often inaccurate tests. As a result, millions of people with active TB survive a long time before diagnosis, or are never diagnosed at all.⁷⁵ In rich countries such as the US,

TB overwhelmingly afflicts low-income people of colour,⁷⁶ who are most dependent on publicly-funded healthcare. In 2017, for instance, New York City's health department reported the largest spike in new TB infections for 26 years, which it attributed to drastic funding cuts for healthcare to vulnerable populations.⁷⁷

Even in countries where treatment for drug-sensitive TB is both affordable and available, many factors contribute to treatment failures which in turn lead to drug-resistant strains of TB. Regimens for multidrug resistant TB (MDR-TB) and XDR-TB take as long as two years to complete, though a new shorter regimen has recently been recommended for specific cases.⁷⁸ Treatment of this kind involves expensive, toxic drugs, hundreds of painful injections, and thousands of pills, with side effects ranging from severe vomiting to blindness.⁷⁹ Recent trials concluded that people living with MDR-TB and HIV face a 22 percent higher risk of developing irreversible hearing loss when they have to use the injectable treatments, than those who are HIV-negative.

Even the most aggressive medicines cure XDR-TB in only 30 to 50 percent of cases.⁸⁰ Even more disturbing than the barely-tolerable side effects for some DR-TB treatments is the fact that the only two effective medicines to treat DR-TB that have emerged in the past 40 years are neither available nor affordable to the vast majority of patients in need. Pricing and registration barriers have severely limited the availability of bedaquiline and delamanid in developing countries, particularly those with the highest burdens of disease. Reports indicate that fewer than 17,000 courses of bedaquiline and 1,500 courses of delamanid have been procured by national TB programmes globally even though approximately 480,000 people fell ill with DR-TB in 2016.⁸¹ Cost remains a key barrier with delamanid available through the Global Drug Facility at a cost of \$1,700 per course of treatment. Yet, studies have shown that large scale generic production of bedaquiline and delamanid could increase the number of patients able to access treatment between five and ten-fold with no increase in procurement expenditure.⁸²

Various human rights declarations and covenants recognise the right to health⁸³ and the right to benefit from scientific progress.⁸⁴ Both the right to health and the right to benefit from science require that new health technologies be accessible and affordable to all who need them.⁸⁵ These

declarations and covenants also guarantee the rights of scientists, inventors, and artists to receive financial rewards of their labours. The balance is not always easy to strike. Still, this latter right belongs only to natural persons, not corporations.⁸⁶ Research and the dissemination of its fruits cannot be guided by corporate priorities nor can they be manipulated to respond only to the drive for profits, for both leave millions behind.

As with HIV and viral hepatitis, HIV and TB each accelerate the progression and complicate the treatment of the other.⁸⁷ HIV, TB, and hepatitis are partners in serious and sometimes fatal health crises. And as with HIV, TB is preventable. Sadly, the levels of investments in TB prevention therapy by most governments remains lamentably low. National programmes for HIV, TB and viral hepatitis should be integrated. In doing so, governments must allocate resources equitably among them, so that none eclipses the other.

A recent open letter by the United Nations Special Rapporteur on the Right to Health to the co-facilitators of the first ever UN High-Level Meeting on Tuberculosis noted that the current level of decline in TB cases would lead to the SDG target of ending TB by 2030 actually only being met by the year 2182. The letter also included this sobering assessment:

“The lack of adequate progress in the TB response can largely be attributed to the failure of States to adopt and implement effective, rights-based, and cost-effective strategies, including universal access to good quality prevention, testing and treatment, including rapid diagnostic tests, new drugs and community-based care, legal protections against discrimination and for privacy and confidentiality, access to information about the disease, its symptoms and prevention and treatment options, and intensified efforts to address stigma and the underlying determinants of health, such as water, sanitation, the environment, housing, and food.”⁸⁸

ONLINE SOLUTIONS, AND CAUTIONS

Equally promising as any new medicine or diagnostic are the innovations in the ways that therapies can be delivered and used. “Self-initiated interventions” (SIIs) include HIV and pregnancy self-tests as well as digital health technologies such as wireless medical devices and mobile health applications with capacity to electronically store, access and

share medical records and information. These can enable people living with HIV and its co-infections to reliably and with less stigma make more informed decisions and take more control of their healthcare at home.⁸⁹ However, SIIs and digital health technologies also present concerns about safety, quality, and effectiveness.

Online buying clubs and markets can provide access to health technologies where they are either unaffordable or legally prohibited.⁹⁰ Social media such as gay dating sites offer forums to talk about HIV, share sero-status, or even receive health reminders.⁹¹ However, the Internet also opens avenues to privacy violations, both intentional and unwitting. Until 2018, the gay dating app Grindr, which has 3.6 million users worldwide, shared information about individuals’ HIV status with two data analytics companies. It did so together with Global Positioning System (GPS) data, phone numbers and emails, potentially enabling the identification of specific users.⁹² In a different incident, a sexual health clinic mistakenly revealed the email addresses of patients receiving their HIV newsletter.⁹³ Data breaches of this kind are not limited to the online sphere. In 2017, in separate incidents, two major healthcare corporations - a pharmacy chain and an insurance provider - revealed the HIV status of thousands of patients by leaving personal information visible through transparent envelope windows.⁹⁴ Depending on the circumstances, such disclosures can lead to stress, job loss, harassment, arrest or incarceration. Key populations in particular have concerns about risks and lack of protections for privacy.⁹⁵ Digital health interventions and healthcare providers that use digital platforms must include stringent protections for user safety and effective safeguards for product safety, efficacy and cost.

RECOMMENDATIONS:

To ensure effective, sustainable health responses consistent with universal human rights obligations, the following measures must be adopted as a matter of urgency:

1. Governments must prohibit in law all forms of discrimination against people living with and vulnerable to HIV, TB and viral hepatitis. Governments must take steps to repeal or amend any laws or policies that discriminate against people based on HIV, TB or hepatitis status.
2. Governments and other funders of biomedical R&D must urgently increase investments in R&D of new health technologies, including diagnostics, medicines and vaccines for HIV, TB and viral hepatitis. Governments and public funders of R&D must consider and implement alternative policies including tax incentives and prize awards to encourage R&D investment by the private sector in neglected diseases such as TB.
3. Governments must ensure that everyone living with or at risk of acquiring HIV, TB, or viral hepatitis has affordable access to the most effective, high-quality health technologies, including diagnostics, medicines and vaccines for HIV, TB and viral hepatitis.
4. Governments must establish legal protections to safeguard the privacy and confidentiality of social media users, digital health technologies, online healthcare records, electronic medical records and communications with healthcare providers. Governments must protect sensitive health information such as HIV status or hepatitis or tuberculosis infection against unjustifiable access and impose strong penalties on those that violate users' rights.



© Edmund Settle – UNDP

There are new pieces of legislation almost every week – on foreign funding, restrictions in registration or association, anti-protest laws, gagging laws...You can visibly watch the space shrinking.

James Savage, Director, Human Rights Defenders Programme, Amnesty International

At the time of the Commission's 2012 report, it was hard to imagine the rise of populism and many of the repressive laws and policies that have emerged since that time. Policies of isolating and suppressing minorities and civil society have proliferated, leading to the disempowerment of both the most vulnerable in society and the organisations that provide essential services and hold governments to account. Denied protection of their human rights, every individual, particularly those living with and vulnerable to HIV, TB, and viral hepatitis, is at risk.

STIFLING CIVIL SOCIETY

Civil society is at the heart of the response to HIV and its co-infections. Between 2012 and 2015, 60 countries passed 120 laws restricting the activities of non-governmental organisations (NGOs) with more than one-third of such laws related to foreign funding of NGOs.⁹⁶ Shrinking civic space not only cripples groups defending human rights and civil liberties, it also enables further repression and condones corruption by reducing the ranks of independent watchdogs of government and corporate entities. New burdens imposed on civil society sometimes threaten health and life as well. This is because NGOs and grassroots community organisations must often act as the *de facto* providers of health, education and social services where governments fail to supply such services. Stigma, criminalisation, and official denial can distort the assessment of need and the success of programmes by driving vulnerable populations underground. The lack of data on these populations creates a paradox which reinforces their invisibility.⁹⁷

REPRESSION, NEW AND RENEWED

Discriminatory “morality” and laws against “promotion of homosexuality” (or “anti-propaganda” laws) are being promulgated in the name of religion or national security. The architects of such laws often proclaim themselves to be defenders of culture and tradition, although many such laws are often remnants of colonial-era statutes. These laws are typically vaguely worded, affording authorities broad latitude in enforcing them. In Algeria, for example, a 2014 iteration of an article of the Penal Code provided fines or imprisonment in the case of any person who possessed, disseminated or displayed anything that constituted a “breach of modesty.”⁹⁸ In Malaysia, the Federal Court overturned a lower court’s decision and restored a ban on “crossdressing” by Muslim transgender persons.⁹⁹

Since 2012, some governments have enacted laws forbidding groups that engage LGBT people to register as officially sanctioned NGOs, striking not just at the activities but also the organisational structures of civil society. Without registration, these groups cannot sign a lease, open a bank account, or apply for a public-assembly permit. China, India, and Russia have blocked donations to HIV-related

human rights NGOs. New laws have interrupted donations from abroad, implying that they constitute covert enemy actions in collusion with local civil society antagonistic to traditional culture.¹⁰⁰

Civil society organisations from a number of African countries report that in spite of constitutional provisions protecting free speech and assembly, civil society activities have been seriously impeded through overregulation, bureaucratic obstacles, surveillance, and funding limits.¹⁰¹ Following the 2013 passage of the Russian Federation law “For the Purpose of Protecting Children from Information Advocating for a Denial of Traditional Family Values,” state-controlled media gave voice to homophobic statements expressed by politicians, religious leaders, and other public figures. Human rights and LGBT rights defenders could not effectively respond as any such response would itself have been classified as “propaganda.” The negative consequences of such laws extend to the beneficiaries of civil society groups who can end up without access to essential health information and services. The “anti-propaganda” law of the Russian Federation also led to a ban by the authorities of web-resources providing basic information on LGBT issues, including on HIV prevention and support for gay and bisexual men living with HIV.¹⁰²

In some instances, civil society is using the law to resist such attacks. For example, in Uganda, litigation led to the invalidation of the Anti-Homosexuality Act that had imposed severe punishments on gay persons.¹⁰³

CLOSING THE FUNDING GAP

According to UNAIDS, donor funding for HIV is currently running \$7.2 billion short of what is needed to end AIDS as a public health threat.¹⁰⁴ Donor government spending on HIV in low- and middle-income countries declined by 13 percent or more than \$1 billion from 2014 to 2015. Latest reports show no significant new commitments from donors and donor government funding has still not returned to its peak level in 2014.¹⁰⁵

The taxonomy of high-, middle- and low-income countries, the analytical classification of the national economies based on gross national income rather than the number of people living in poverty or wealth distribution, has further muddied the waters. This taxonomy has no reflection in international human rights law, nor is it reflected in the SDGs. It is therefore not permissible to diminish or deprive individuals of human rights guaranteed by law on the basis of economic classification, however convenient this taxonomy may be for other purposes.

As economic growth moves poorer countries to middle-income status in the international classification of overall national wealth, their eligibility for donor assistance diminishes. And yet two-thirds of the poor and the majority of people with TB and untreated HIV live in middle-income countries.¹⁰⁶ Funding strategies of health donors encourage countries to assume more of the burden. In 2016, domestic resources accounted for 57 percent of resources for HIV in low- and middle-income countries.¹⁰⁷

Of an estimated \$9.2 billion per year needed to adequately support TB prevention, diagnosis and treatment, only \$6.9 billion was made available in 2017.¹⁰⁸ The total cost of implementing WHO's Global Health Sector Strategy on Viral Hepatitis for 2016–2021 is \$ 11.9 billion alone¹⁰⁹; much more by way of donations is needed to meet this target.¹¹⁰ Advocates express concern that the slow pace of reducing new HIV infections compared with galloping increases in TB and hepatitis will fuel "AIDS fatigue" and lead donors to neglect HIV even further. Of course, donors will set their own priorities.¹¹¹ Unfortunately, the needs of people living with and vulnerable to HIV, TB and viral hepatitis may not neatly conform to categories determined by governments, philanthropic bodies and multilateral organisations. Vulnerable and marginalised people will certainly be left further behind.

DONOR PRIORITIES

How will countries that struggle to provide the most basic healthcare make up the growing shortfall in donations? The answer is that some will not. If past experience is anything to go by, the first subventions to fall will be those supporting human rights programming. Already such programmes are limping along, wounded by the decline in funding. In 2015 UNAIDS calculated that \$137 million was provided for the global human rights response to HIV each year, a fraction of spending on the overall HIV response in low- and middle-

income countries alone. Among so called low- and middle-income countries reporting to UNAIDS, a mere 0.13 percent of total AIDS spending was allocated for human rights advancement. Most HIV organisations naturally integrate the protection of human rights into their advocacy and services. With smaller donations anticipated, however, these organisations expect to see the capacity to advance HIV-related human rights decline even further.¹¹² As for the often slower and longer-term work of legal and policy reform, a lack of adequate data makes it is hard to know either how much is spent or how much of that money remains available.

The fact that only 1% of overall global AIDS resources address human rights programming offers a critical and urgent opportunity for private philanthropy to exercise its unique power to fund where others won't, and to mobilize civil society to hold all donors accountable to their commitments to fully fund efforts to combat those human rights abuses that have long fuelled the epidemic.

**John Barnes, Executive Director,
Fundors Concerned about AIDS**

The example of Romania illustrates how diminishing resources and the denial of human rights combine to hurt people in need. With Global Fund support, Romania launched a highly praised needle and syringe exchange and opioid substitution programme in 2010. Then, under the new Global Fund policy transitioning out of middle-income countries, Romania lost the Global Fund's support. The government did not fill the gap, with dire consequences for many individuals: HIV prevalence among people who inject drugs surged from 3.3 percent in 2009 to 27.5 percent in 2013. A specific HIV outbreak among drug users around 2011 has been directly linked to the significant decline in harm reduction services following the Global Fund transition out of the country.¹¹³

INEQUALITY AND SOLIDARITY

When international donations decline, global bodies remind donors of their obligations to uphold economic solidarity. Some countries step in when other countries step back, as when the restoration of the US "global gag rule"

in 2017 inspired a range of countries to contribute to the Netherlands-led “She Decides” Fund, which aims to promote access to family planning goods and services, sex education, safe abortion, and maternity care.¹¹⁴

While development slowly narrows the gap between countries, income and wealth inequalities *within* countries are widening. Between 2012 – 2016, 10 percent of the top income earners received 63 percent of the national income in South Africa; 55 percent in Brazil and 47 percent in the US.¹¹⁵

In Africa the countries with the highest HIV prevalence—in order, Swaziland, Lesotho, Botswana, South Africa, and Namibia,¹¹⁶ are also the world’s seven most unequal economies in terms of wealth distribution.¹¹⁷

As they assume more of the costs of HIV and its co-infections, national governments will be compelled to identify efficiencies.¹¹⁸ Progressive taxation, such as Zimbabwe’s 3 percent AIDS levy on individuals’ income and corporate profits¹¹⁹, could potentially contribute to rebuilding public infrastructure and meeting the needs of people living with HIV, TB or viral hepatitis.

More wealth in fewer hands creates more poverty.¹²⁰ The importance of eradicating poverty is recognised by the first SDG. A commitment to attacking today’s growing economic inequalities is a pledge to solidarity and to the rights, health, and well-being of all the world’s people.

PRIVATE SECTOR RESPONSIBILITY

Given the increasing globalised economic role that the private sector plays, its role in fighting HIV, TB and viral hepatitis has become more important than ever.

Standards of conduct for business, such as the ones developed by the UN Office of the Commissioner for Human Rights on tackling discrimination against LGBT people,¹²¹ are a new approach to harnessing the potential of the private sector for societal improvement. Many of the companies that have committed to the business standards argue that improved conditions for LGBT people will ultimately benefit their company’s moral and economic bottom line.¹²²

Other companies have opted to support efforts in the fight against HIV more directly. For example, Viiv Healthcare, a

producer of ARV medicines, started a foundation supporting civil society groups working on HIV particularly groups working with key populations.¹²³ Product (Red) is an example of companies coming together to increase resources for Global Fund-financed programmes.¹²⁴

Biomedical companies have a specific role to play in the fight against HIV, TB, viral hepatitis and other epidemics. While some producers of ARV medicines, and in particular some patent holders, have been accused of price gouging,¹²⁵ in several cases this has led to reduced prices for poorer countries as patent holders grant the right to manufacture cheaper generic medicines. Companies benefitting from epidemics have a special role to play in making and keeping medicines accessible for all in need.

The private sector can also support HIV and sexual health efforts by connecting dating site or application users to health services and facilitating awareness among vulnerable groups of the availability of medicines.

SURVEILLANCE, VIRTUAL AND ‘INTELLIGENT’

For people living in repressive spaces, cyberspace can be an open civic space, a place to connect with partners, friends, associates and allies, to access and share information, including on sex education or information on safe practices. Yet a range of governments are increasingly monitoring and censoring the use of the Internet by groups and individuals whom they deem to be undesirable. In 2017 there was a dramatic increase in efforts by governments to manipulate information on social media, censor mobile connectivity, restrict video streaming, arrest people trying to record human rights abuses, and carry out cyberattacks on news outlets, political opposition and human rights defenders.¹²⁶

In 2016, 38 countries initiated criminal processes based on social media posts or sharing or “liking” content on Facebook. Thirty countries engaged in political interference of discussion on social media, disseminating misinformation, attacking opponents, and fuelling violence. Some governments are using social media platforms like Facebook and Instagram to identify and arrest gay people and those who “follow” them.¹²⁷ In addition to violating privacy, this is making it more difficult to use these platforms to provide essential health and rights information.

Other new technologies present potential for misuse. Of particular concern has been the advent of artificial intelligence facial recognition. Police and immigration authorities use this software to identify criminal suspects. However, critics say the systems are no more than crude, inaccurate racial profiling dressed up as science.¹²⁸ Several academics have published research concluding that facial recognition technology could also identify the subject's sexual orientation.¹²⁹ The article, which appeared to lack peer review, has been dismissed by critics as "junk science."¹³⁰ Nevertheless, employed without the subject's knowledge or consent, artificial intelligence facial recognition of this kind violates the right to privacy of those affected.

BARRED BORDERS

Repressive legislation extends to immigration, affecting migrants seeking new homes for their families. Globally, there are an estimated 258 million migrants, 28.5 million of whom are refugees and asylum seekers.¹³¹ For migrants

living with HIV and its co-infections, repressive laws and policies can be life-threatening.

While images of migrants on the move to Europe in search of safety and opportunity is widely covered in international media, in fact the developing world, including some of the world's poorest countries, hosts 84 percent of the world's displaced persons.¹³² Even in countries with well-financed systems for processing migration and asylum applications, new and harsh laws exclude undocumented migrants from national or local services or social insurance programmes essential to human existence and survival.¹³³

FEAR OF CONTAGION

Migration, especially when caused by sudden and dangerous events, frequently exposes those involved to fatigue, malnutrition, shortages of water and inadequate access to treatment. These conditions are great challenges to human health. In some regions, migration itself is



an independent risk factor for HIV and other infections and diseases.¹³⁴ In South-East Asia, for instance, the HIV prevalence among migrants to Thailand from Cambodia, Myanmar, southern China and Vietnam is up to four times that of their respective general populations.¹³⁵ Health risks are exacerbated in areas of armed conflict, where healthcare facilities are demolished and healthcare workers flee, along with other residents. The same is true of countries such as Venezuela, which since 2015 has seen AIDS deaths double because of an ongoing economic and political crisis.¹³⁶ Some groups of migrants bear a higher risk of TB depending on their places of origin, yet they face barriers in accessing treatment, care and support services.¹³⁷

Immigration authorities may use health status to set conditions on the provision of visas. They may decline to issue visas or decide to deport foreign nationals. According to researchers, the United Arab Emirates requires any foreign national applying for a work permit to be tested for HIV with the result that those found to be HIV-positive are liable to be deported immediately.¹³⁸ Such policies violate the universal human rights to confidentiality and informed consent, privacy, bodily integrity, and medical care. The fear of deportation or of being denied refugee status based on HIV-positive status may discourage people, rather than encourage them, from accessing testing and, where available, ART or other healthcare. In the case of TB, deportation can also increase the risk of treatment interruption. This in turn increases the likelihood of developing drug-resistant forms of TB.¹³⁹

Recent epidemics such as severe acute respiratory syndrome (SARS) and Ebola, as well as instances of bioterrorism have heightened the vigilance and hostility of many governments. Tougher immigration policies can reinforce myths about infections and distort public health messages and responses.¹⁴⁰ This is especially so for stigmatised diseases like HIV and TB which may be viewed as “foreign” imports.

THE RIGHT INTENTIONS

Human rights instruments since World War II reiterate and elaborate the principles that all migrants are entitled to freedom from arbitrary detention, slavery, torture, and to the enjoyment of rights such as the rights to health, housing, and education.¹⁴¹ Recent reports stress the importance of keeping the administration of general public services separate from immigration enforcement.¹⁴² However, the asserted right of nations to regulate immigration can conflict with this basic human right to sanctuary.¹⁴³

Domestic statutes sometimes affirm universal human rights principles and guarantee access to HIV and health services to migrants. For instance, laws in several European countries entitle migrant children access to the same healthcare as their nationals receive. Sometimes they cover migrants’ healthcare costs.¹⁴⁴ It is unclear whether these laws are being implemented.¹⁴⁵ For example, across the European Union, unaccompanied refugee children are frequently denied healthcare, education, and permanent housing. In 2017 the British press revealed that the NHS was turning away thousands of undocumented migrants in the UK in need of urgent healthcare.¹⁴⁶ Effective implementation of inclusive laws which grant access to healthcare services to migrants can only contribute to stemming the tide of HIV and its co-infections.

RECOMMENDATIONS:

To ensure effective, sustainable health responses consistent with universal human rights obligations, the following measures must be adopted as a matter of urgency:

1. Governments must stop the use of laws restricting the registration and operation of civil society organisations or their sources of funding to curtail their activities. Where any such laws have been enacted, countries must repeal, or refrain from enforcing, them.
2. Governments must enact laws that provide an enabling environment for civil society organisations to operate, including those providing services to populations living with or affected by HIV, TB or viral hepatitis.
3. Governments must refrain from enacting laws that require non-heterosexual sexual orientations to be portrayed as inherently inferior.
4. Donors and governments must sustain support to civil society programmes and legal reform efforts aimed at defending and promoting the human rights of people living with HIV, TB, and viral hepatitis, particularly for marginalised groups.
5. Assuming that the transition from international to domestic funding continues, donors must ensure that they do not desert countries with inadequate resources for effective responses to HIV and its co-infections.
6. Governments must assume greater responsibility for financing their HIV, TB and viral hepatitis responses. This includes ensuring sufficient investment in human rights programmes for law reform and access to justice.
7. Governments and the private sector must adjust their policies and subventions for universal healthcare to focus on the rights of individuals to access the highest attainable standard of health. They must not derogate from individual rights provided in international human rights law by reference to economic classifications of national wealth that result in derogations from these human rights.
8. Governments must prohibit the non-consensual use by law enforcement or private entities of digitally-collected or stored private information, especially data related to sexual and reproductive health. Such data must not be used for discriminatory purposes or for commercial surveillance, profiling or targeting, except as provided by law, with the informed consent of the subjects and in circumstances consistent with universal human rights.
9. Governments must stop the censorship and restriction on internet access and communication except where provided by law that is consistent with universal human rights law. Government must facilitate the use of internet and evidence-based information, education and communications platforms to promote access to health and rights information and services.
10. Governments must refrain from denying entry, restricting their travel within national borders or deporting people with HIV, TB or viral hepatitis based on their positive status. Countries must repeal such laws where they exist.
11. Governments must not mandate universal HIV, TB or viral hepatitis testing of foreign nationals. If such laws or policies exist, they should be repealed or abolished. Any requirements to undergo such tests should only occur where provided for by law, for proper purposes consistent with universal human rights law.
12. Governments must provide migrants, including asylum seekers or refugee applicants, access to the full range of health services including for HIV, TB and viral hepatitis regardless of immigration status. Governments must provide this standard of care in detention and confinement settings.
13. Governments must amend laws and policies that deter health seeking among migrant populations, such as requirements to show national identification documents, residence cards, or to only receive treatment in their home region or country.

PUNISHMENT



© Josh Estey-AUSAID

The use of laws and policies to discriminate against people living with HIV, TB or viral hepatitis, or to criminalise sex work, drug use, same sex relations or expressions of identity, are often enacted and enforced in the name of public health and safety. However, they usually result in the opposite, especially for marginalised groups. These laws can be considered “status offences” insofar as they criminalise categories of people seen as deviant, immoral or subversive. People have several intersecting identities. They may not just be a transgender woman or a person who uses drugs. They may also be a sex worker, a refugee or a member of a racial minority. Thus, repressive laws affect people in multiple ways, to the detriment of their health, freedom and well-being.

PEOPLE WITH HIV

In 2012, the Commission reported that 60 countries had criminal or civil laws penalising HIV non-disclosure, exposure or transmission, even if unintentional.¹⁴⁷ As of July 2018, 68 countries criminalise HIV non-disclosure, exposure or transmission or allow the use of HIV status to enhance charges or sentences on conviction. Sometimes statutes allow the use of HIV status to enhance or aggravate criminal

Most [HIV criminalisation] laws are appallingly broad, and many of the prosecutions under them have been wickedly unjust. HIV criminalisation is bad, bad policy...It undermines the remarkable scientific advances and proven public health strategies that open the path to vanquishing AIDS by 2030.


Edwin Cameron,
Justice of the Constitutional Court of South Africa

charges or sentences. Not all countries with HIV-specific laws have enforced them. Other countries have applied general laws, such as attempted murder, poisoning, bodily harm or sexual assault laws against people living with HIV. As of September 2017, HIV prosecutions had been reported in 69 countries with Belarus, Russia, Canada and the United States in the top four.¹⁴⁸ As more countries heed advocacy to repeal HIV-specific criminalisation laws, attention must be paid to these overly broad general laws which have the potential of being used to prosecute not only people living with HIV, but also people with HIV-co- infections.¹⁴⁹

Conviction for an HIV-related sex offence carry even graver consequences than the primary custodial or financial punishment as lawmakers impose longer prison sentences for “sex offenders”, as well as imposing the requirement to list in public sex offender registers, crippling restrictions on work, residence, travel and family relations, and deportation of non-citizens.¹⁵⁰

These laws blatantly disregard up-to-date knowledge on the science of HIV-related risks and harms.¹⁵¹ Recent research strongly supports the findings of the Commission’s 2012 report that HIV criminalisation fails to encourage safer behaviour; it may even result in greater risks.¹⁵²

PROSECUTING THE VIRUS



Source: HIV Justice Network. Countries where prosecutions have ever taken place [as of September 2017]. Available at <http://www.hivjustice.net/site/countries/>

The safety of my office was shattered and physician-patient privilege was lost by the intrusion of these criminalisation charges... Nearly 30 percent of my colleagues confirm that they too have had criminal prosecutions invade their patient relationships. Criminalization laws do nothing to advance individual or public health, but...have the potential to corrupt the physician-patient relationship which I believe can be a powerful tool in the armamentarium to address the epidemic.

Wendy Armstrong, Director, Infectious Disease Fellowship Training Programme, Emory University, US

prosecutor congratulated her on helping put a “scumbag” behind bars, the doctor felt defeated as her fundamental oath to “do no harm” had been violated and she was reduced to a person who had harmed, rather than helped, her patient.¹⁵³

My life will not be the same after facing HIV criminalisation. My 30 years as a nurse and dedicated to saving lives have been erased. I have spent almost a year in prison. I have been branded a criminal and a killer even though I have harmed no one.

Rosemary Namubiru, convicted Ugandan nurse living with HIV

Less often discussed, however, is the impact of these laws on healthcare professionals. A physician compelled to testify in the US at the criminal trial of her HIV-positive patient described being put in the position of betraying both her own ethics and the patient’s privacy and trust. When the

JUSTICE AND SCIENCE

The proved fact that a fully suppressed viral load means a zero chance of HIV transmission¹⁵⁴ can help lawyers defend clients who face harsh penalties for allegedly exposing sexual partners to HIV. However, advocates worry that using suppressed viral load as an argument for innocence can imply that those who are less able to achieve viral suppression, owing to a range of social or economic determinants, are more likely to be found guilty, exacerbating biases in criminal legal systems against people who may be the least able to access care.¹⁵⁵

Phylogenetic analysis, a methodology by which scientists can compare partial DNA or RNA sequences from different sources to infer evolutionary relationships among them, has given scientists great insight into HIV transmission and prevention. Phylogenetics can definitively rule out a link between one person's HIV and that of another person if the strains are different. However, phylogenetics has severe limits as a forensic tool because even where it establishes a link between two people, it cannot confirm the direction or time of transmission, that is, whether person B contracted HIV from A or vice versa or from a third person C who may have contracted it from A.¹⁵⁶ Thus, phylogenetics cannot prove a connection beyond reasonable doubt.¹⁵⁷

Another troubling development is the potential misuse of phylogenetics in disease surveillance programmes. Epidemiologists can analyse DNA data derived from HIV drug-resistance tests to identify molecular or transmission "clusters"¹⁵⁸ with the intention of containing the virus. However, people living with HIV fear that this confidential information could sometimes be used coercively or punitively against individuals.¹⁵⁹

SEX WORKERS



The consensus reached by the 2030 Agenda is an extraordinary opportunity to consolidate achievements in terms of women's rights, promoting the right to decent and recognised work, as well as access to health services for the prevention of HIV... Sex workers are not the problem but part of the solution.

RedTraSex Latin America Network of Sex Workers

Female sex workers are on average 13.5 times more likely to be living with HIV than women of reproductive age.¹⁶⁰ As described in the Commission's 2012 report, sex-work-related violence, stigma, and most of all, criminalisation, exacerbate the risk of contracting HIV.

In recent decades in several countries, sex worker policy has been influenced by a framing of the sex worker as victim and the client as exploiter, thereby rejecting a scenario where adult parties engaged in a voluntary and consensual exchange of services for financial and other benefits. The "end-demand," or "Nordic," model exemplifies this approach. It criminalises clients rather than sex workers. Although it is not clearly established that such initiatives deter or reduce sex work or HIV transmission,¹⁶¹ several countries, including Canada,

France, and Northern Ireland, have enacted similar laws, promoting them as a progressive response to an age-old conundrum.¹⁶²


The Swedish Sex Purchase Act of 1999, which criminalises the client and those living off the earnings of sex work, is held up as a success story by the Swedish government.¹⁶³ However, some Swedish and international scholars question their assessment.¹⁶⁴ A 2014 review of the legislation by the Swedish Association for Sexuality Education and Malmo University found that it was unclear to what extent mobile phones and the Internet, rather than the law, may have accelerated the reduction in street sex work by bringing buyers and sellers together electronically.¹⁶⁵ Another 2014 study, supported by Sweden's Public Health Agency, revealed problems for sex workers in accessing healthcare and HIV prevention, as well as sex workers' lack of confidence in the authorities and a reluctance both to contact health services and get tested for HIV and other STIs.¹⁶⁶ The study also revealed that stigma against sex workers remains widespread, making it difficult

for sex workers to get help from social services and the police, and stoking their fear of eviction or loss of custody of their children.¹⁶⁷

After France adopted the "end-demand" model in 2016, the majority of nearly 600 sex workers surveyed a year later by an international humanitarian aid organisation said the new law had a detrimental effect on [their] safety, health and overall living conditions. Thirty-eight percent said it negatively affected their ability to negotiate safer sex as male clients felt that the burden of legal risk was no longer on the sex worker but on them, the clients under the new law.¹⁶⁸ In all, 88 percent of the sex workers surveyed opposed the criminalisation of clients.¹⁶⁹

As increasing numbers of sex workers go online to advertise services and conduct business transactions, lawmakers are also adopting laws to "protect" them in cyberspace. In 2018, the United States enacted the Allow States and Victims to Fight Online Sex Trafficking Act (FOSTA). This makes it easier

IMPACT OF CRIMINALISING SEX WORKERS' CLIENTS IN FRANCE



Source: Le Bail H. and Giametta C. (2018), *What do sex workers think about the French Prostitution Act: A study on the impact of the Law from 13 April 2016 against the 'prostitution system' in France.* Figures represent the % of the 583 sex workers who took part in the survey. Available at <https://www.medecinsdumonde.org/sites/default/files/ENGLISH-Synth%C3%A8se-Rapport-prostitution-BD.PDF>

for individuals and law enforcement to shut down websites which they assert are abetting trafficking by accepting sex advertisements.¹⁷⁰

Sex worker organisations that lobbied unsuccessfully to stop the law claimed that FOSTA would rob them of independence, income and safety by driving their work underground. It would send them onto the street where they were more likely to get arrested, and it would block channels through which they could share information and access peer-counselling.¹⁷¹ The use of online platforms to advertise their services enhances sex workers' safety, autonomy, and control over their working conditions. Although mainly American-owned, such Internet platforms are global, so sex workers are potentially affected worldwide.

The evidence is stronger than ever that criminalisation of sex work results in a heightened HIV risk and "end demand" models do not lessen it.¹⁷² A review of 27 countries found that "countries that have legalised some aspects of sex work have significantly lower HIV prevalence among sex workers," especially if such legalisation operates in concert with fair and effective law enforcement.¹⁷³ Another study concluded: "Decriminalisation of sex work would have the greatest effect on the course of HIV epidemics across all settings, averting 33 to 46 percent of HIV infections in the next decade."¹⁷⁴

PEOPLE WHO USE DRUGS

Drugs have destroyed many lives, but wrongheaded governmental policies have destroyed many more. I think it's obvious that after 40 years of war on drugs, it has not worked.

Kofi Annan, former UN Secretary General

Levels of HCV co-infection are extremely high among people who use drugs.¹⁷⁶ Of an estimated 15.6 million people who inject drugs worldwide, almost one in six are living with HIV. Over half have HCV.¹⁷⁷ Criminalisation of the possession, use and cultivation of small amounts of illicit drugs leaves a trail of damage for people living with HIV and its co-infections. As described in the Commission's 2012 report, criminalisation drives people who use drugs underground. This leads to

unsafe practices which, in turn, increase the risk of infection for both them and their sexual partners in the wider community. A 2017 systematic review further supports this finding, concluding that criminalisation of drug users undermines HIV prevention and treatment.¹⁷⁸

PEOPLE IN PRISONS

Criminalising the possession and use of even small quantities of illicit drugs means that many would-be law-abiding people who use drugs run the risk of imprisonment. In one study, over 60 percent of people who inject drugs had been incarcerated at some point in their lives.¹⁷⁹

Incarceration increases susceptibility to disease.¹⁸⁰ Needle-sharing and tattooing contribute to HIV rates as high as 40 percent among people who inject drugs in prison,¹⁸¹ where the risk of developing active TB is 23 times higher than average.¹⁸² The UN Standard Minimum Rules for Treatment of Prisoners, promulgated in 1955 and now called the Nelson Mandela Rules, mandate that prisoners should "enjoy the same standards of healthcare that are available in the community," without charge or discrimination. This is to include "continuity of treatment and care, including for HIV, viral hepatitis, TB and other infectious diseases, as well as for drug dependence."¹⁸³ Unfortunately, most prisons around the world are not following these rules. Only 40 countries have at least one prison that offers access to HIV treatment or opioid substitution treatment (OST).¹⁸⁴

The situation outside the prisons is not much better: Less than 1 percent of people who inject drugs live in countries where needle syringe exchange and OST levels are categorised as high, that is, more than 200 needle-syringes distributed per year per person who injects.¹⁸⁵

Progress, when it occurs, is too slow. After 20 years of pressure from public health experts and advocates, including through litigation before the courts, in 2018 the Canadian government finally conceded to provide needle-exchange programmes in prisons.¹⁸⁶

TREATMENT DENIED OR COMPELLED

In spite of their high susceptibility to illness,¹⁸⁷ people who use drugs are commonly barred from HCV treatment programmes, some pre-emptively, others

From “objects to subjects”

For two decades the members of the Network of Sex Workers of Latin America and the Caribbean (RedTraSex) have been empowering themselves to create a legal environment in which they can perform their work safely and with dignity acceptable to themselves. Working in 14 countries, RedTraSex has won legal recognition as an industrial union in Argentina, Colombia, Guatemala, Nicaragua and Peru. The group has published guidelines for unbiased and respectful healthcare practices, trained 8,900 law enforcement officials across the region between 2013 - 2018, and persuaded police and prosecutors to address legal and human rights violations by security and police, including extortion, theft, and forced sex. In 2017 the sex workers prompted the Inter-American Commission on Human Rights (IACHR) to hold its first hearing for women sex workers. After this gathering, the IACHR urged Member States in the region to design regulations and policies guaranteeing the human rights of sex workers, including measures to protect their lives and end stigmatisation and discrimination against them.

“We went from being objects to subjects of policies and actions in favour of ourselves,” RedTraSex wrote. “[Persecution has] united us, forged our identity as sex workers and . . . encouraged us to establish our organisations, instead of lowering our heads.”¹⁷⁵

through burdensome counter-productive bureaucratic requirements.

At the same time, some jurisdictions force people with TB to undergo treatment and, if they resist, they are detained and compelled to submit to treatment. In Kenya TB patients who do not adhere to their TB treatment risk custodial sentences. In 2016 three Kenyans successfully challenged their eight-month prison sentence.¹⁸⁸ In some places, expectant mothers who use drugs are detained and forced into drug treatment, sometimes for the duration of their pregnancy.¹⁸⁹

The ramifications of abandoning people who use drugs can be severe. When authorities of the Russian Federation abruptly ended methadone treatment in Crimea in 2014 when that territory was seized from Ukraine, patients went back to street drugs. Some left Crimea. Many died.¹⁹⁰ In 2016 the Russian Federation acknowledged its millionth case of HIV, with the epidemic leaking from the margins back into the general population.¹⁹¹

‘UNFIT’ MOTHERS

For women, the intersection of poverty, criminalisation, motherhood, and illicit drugs can be deadly. Poorly educated women in poorer countries are often forced into the drug trade, in Latin America as “mules” smuggling

contraband over borders,¹⁹² or in Thailand, Afghanistan and Myanmar as small farmers cultivating opium poppies.¹⁹³ For these minor sometimes coerced acts, women face harsh penalties that may exceed those commonly imposed for rape or murder.¹⁹⁴ International and domestic anti-drug policies are the leading cause of the rising incarceration of women.¹⁹⁵ Once in prison the likelihood of female prisoners contracting HIV, TB or viral hepatitis climbs significantly.

Women who use illicit drugs are often designated by authorities as unfit mothers.¹⁹⁶ In some jurisdictions in the US, a history of drug use can trigger loss of parental rights for female prisoners.¹⁹⁷ Pregnant women who want to quit drugs or get ART to protect their children instead avoid clinics due to the risk of losing their children.¹⁹⁸ In Estonia, “when women call the police in cases of aggressive behaviour by their male partners, the police often inform child protection services. This may result in the loss of custody of the child. The police may also prosecute a woman for a drug offence, instead of protecting her from violence.”¹⁹⁹ Mothers may be forced to stop OST against WHO recommendations, in order to maintain custody of their children. If an active drug user gives birth in prison, the authorities commonly take away custody of the baby who is raised separately.²⁰⁰



Underlying these practices are widespread stereotypes and myths about people who use drugs:

- They are reckless, weak-willed, and self-destructive;
- They will not comply with treatment for their addictions; and
- Their behaviours will render HIV, TB or viral hepatitis treatment ineffective.²⁰¹

In fact, people who use drugs ordinarily adhere to treatment as faithfully as other groups.²⁰² HCV therapeutics are effective even for people who continue to inject drugs, particularly if they are also on ART.²⁰³

END THE WAR

The first step to alleviating these miseries is to decriminalise the possession or cultivation of drugs for personal use and to correct the imbalance in global drug policy that skews the governing policy towards law enforcement at the expense of human rights and public health.²⁰⁴ The outcome

document of the 2016 United Nations General Assembly Special Session on the World Drug Problem²⁰⁵ won praise in many quarters as the strongest endorsement of a rights-based approach ever adopted in a UN drug control measure.²⁰⁶ In 2018, the UN Commission on Narcotic Drugs for the first time approved a resolution to remove stigma as a barrier to healthcare and services for people who use drugs.²⁰⁷ These developments are an encouraging sign of progress. However, without a systematic effort to embed human rights principles in drug control laws and policies, progress is likely to be very limited. In response, a broad coalition of lawyers, political leaders, academics, civil society, communities of people who use drugs and UN organisations is presently developing International Guidelines on Human Rights and Drug Control.²⁰⁸

RECOMMENDATIONS:

To ensure effective, sustainable health responses consistent with universal human rights obligations, the following measures must be adopted as a matter of urgency:

1. In countries where HIV criminalisation laws still exist, courts must require proof, to the applicable criminal law standard, of intent to transmit HIV. The intent to transmit HIV cannot be presumed or derived solely from knowledge on the part of the accused of positive HIV status and/or non-disclosure of that status; from engaging in unprotected sex; by having a baby without taking steps to prevent mother-to-child transmission of HIV; or by sharing drug injection equipment.
2. Governments must ensure that, where an HIV-specific law has been repealed, there is a restriction on the application of any general laws to the same effect either for HIV or TB.
3. Governments must prohibit the prosecution under HIV-specific statutes, drug laws, or child abuse and neglect laws, of women living with HIV for choices they make during and after pregnancy, including about breastfeeding children.
4. Whenever HIV arises in the context of a criminal case, police, lawyers, judges and where applicable, juries, must be informed by the best available scientific evidence concerning the benefits and consequences of appropriate therapy, and the individual and community advantages of maintaining such therapy.
5. Governments must ensure that HIV status is not used to justify pre-trial detention, segregation in detention or prison, or harsher or more stringent sentences or conditions of parole or probation following release from custody.
6. Governments must refrain from adopting laws based on the “end-demand” model of sex work control and repeal such laws where they exist.
7. Governments must not pass laws prohibiting, penalising, or enabling legal action against Internet site owners or other media interests that accept advertisements for sex work. If such laws have been adopted the governments concerned must repeal them.
8. Governments must not employ coercive methods or confinement during treatment of persons who use drugs nor detain or imprison anyone for failure to take up, adhere to or successfully complete HIV, TB or viral hepatitis therapy or drug dependence treatment.
9. Governments must repeal laws or regulations that mandate total abstinence from drug use as a pre-condition for accessing treatment for HIV, TB or viral hepatitis.
10. Governments must make every effort to ensure that incarceration is a last resort for drug use and drug-dependence offences and should instead promote alternatives to incarceration for drug use, and drug-dependence offences.
11. Governments must adopt legal protections to prevent discrimination against people who use drugs.

FURTHER BEHIND



ADOLESCENT GIRLS AND YOUNG WOMEN

As a young woman living with HIV, I want to see the integration of HIV and sexual and reproductive health services in one place.

Tranisha Arzah, peer advocate, Seattle, Washington

Sexual and reproductive health and HIV are closely linked. The same adolescent girls and young women disproportionately affected by HIV also face barriers to sexual and reproductive health services. Women living with HIV are more likely to experience violence,²⁰⁹ including violations of their sexual and reproductive rights.²¹⁰ Involuntary and coerced sterilisation and forced abortion among women living with HIV have been reported worldwide.²¹¹ Mandatory HIV testing for pregnant women may be a barrier to antenatal care. Legal barriers to sexual and reproductive care also impede progress in addressing HIV.

The Commission's 2012 report discussed the multiple and intersecting conditions, including legal barriers, which leave women and girls particularly vulnerable to HIV.²¹² By almost every measure of vulnerability, women, including transgender women, are disadvantaged in comparison to men.²¹³ Today it is clear that adolescent girls and young women are uniquely endangered. In 2015, adolescent girls and young women comprised 60 percent of those aged 15 to 24 years living with HIV and almost the same percentage of new HIV infections were among this cohort. There is no region in the world where HIV prevalence among females aged 15 to 24 does not exceed that among older women.²¹⁴ Worldwide, only 22 percent of females aged 15 to 24 years old have access to contraceptives, compared with 60 percent of women over 30.²¹⁵ Sexual and reproductive health services are unavailable to unmarried women in much of the world.²¹⁶ While there has been some progress on ending child marriage, one in four girls worldwide is married before she turns 18, in some places far younger than that, thereby increasing HIV risk.²¹⁷

The rights of girls and young women with disabilities are diminished by multiple perils.²¹⁸ Families and educators avoid talking to them about their bodies and feelings. Girls and young women with disabilities are often shamed, demeaned, and married off to anyone who will accept them, irrespective of their wishes.²¹⁹ They are more at risk of contracting HIV than boys and young men of the same age, yet they are less likely to receive information about safer sex, testing, or treatment.²²⁰

Globally, law and policy in more than 70 jurisdictions currently allow healthcare providers to refuse to provide health services to girls and young women based on claims of "conscience."²²¹ While these claims are mostly invoked in the case of the termination of pregnancies, reports suggest that healthcare providers are increasingly using "conscience" claims to deny access to contraceptives including condoms, and to refuse treatment to LGBT people and their families as well as women seeking sexual and reproductive health services.²²² Various human rights declarations and covenants protect the freedom to hold and express religious and ideological beliefs. However, they do not recognise a right of conscientious objection when those beliefs conflict with someone else's rights to health and life.²²³

For more than a quarter of a century, human rights advocates have asserted that sexual and reproductive health and rights are basic human rights.²²⁴ The right to sexual and reproductive health free from coercion, discrimination and violence is widely recognised in both international human rights treaties and normative documents. For example, the African Union's Maputo Protocol guarantees women's rights to health including sexual and reproductive health.²²⁵ Such commitments should be more extensively and consistently reflected in national laws. Countries must also act to remove legal barriers such as criminalisation, discrimination and violence in healthcare settings.²²⁶

GAGGED

Unless we can fill the \$80 million gap created by the "global gag rule", it will deprive millions of women of the contraception they need to prevent an unintended pregnancy, and it is the world's poorest women and girls who will bear the brunt.

Marjorie Newman-Williams, Marie Stopes International

The defence of sexual and reproductive rights and the delivery of healthcare services costs money. In 2017 the US—the world's largest HIV, health and family planning donor—began severely restricting the flow of funds by reinstating and expanding its Mexico City Policy, also known as the "global gag rule". This rule prohibits foreign organisations that receive family planning funds, now any health-related funds, from providing information or even talking about abortion. When this rule was previously reinstated in 2001, the loss of services resulted in more unsafe abortions in sub-Saharan Africa.²²⁷ The "global gag rule" forces organisations to make an excruciating choice to either forgo providing women and girls with a full range of sexual and reproductive health services or to shut down other crucial programmes such as HIV prevention and treatment, and maternal and child health services.

The 2017 "global gag rule" is already causing harm. An example is Family Health Options Kenya. Unable in good conscience to cease providing abortions in a country where the procedure is legal yet unsafe abortion is the leading cause of preventable death among women and girls of reproductive age, Family Health Options turned down grants

from US sources representing 60 percent of its budget. Immediately, it was forced to close a clinic and cancel 100 planned events.²²⁸ A nurse made the loss concrete by recalling a 13-year-old incest victim who arrived “suicidal.” She had

tried to end her pregnancy using herbs. Fortunately, that girl was able to safely terminate her unwanted pregnancy. Now others in similar situations will be forced to resort to risky, sometimes deadly, do-it-yourself measures.²²⁹

Boys and men: The price of masculinity

Harmful framings of masculinity, expressed in everything from domestic abuse to discriminatory laws, have adverse effects on women and girls. But such masculine norms can also hurt boys and men and put them at risk of acquiring HIV, STIs, and co-infections. Definitions of manhood that prioritise toughness and silence discourage boys and men from practising safe sex, getting tested for HIV, seeking and adhering to treatment, or even talking about sexuality. In all these areas, women do better than men. The notion of male invincibility encourages the overconsumption of alcohol and drugs, both risk factors for HIV. Stereotypical ideas of manliness also promote homophobia and transphobia. Stigma, harassment and criminalisation keep gay men and transgender people from seeking health services. Globally, men who have sex with men are 24 times more likely to acquire HIV than the general population. The risk to transgender women is 49 times higher. Male sex workers and men who inject drugs have higher HIV infection rates than women in the same key populations. TB rates are also higher among men. One contributor is that TB is ubiquitous in prison, where 90 percent of inmates are male. A transformation of harmful gender norms would benefit everyone, regardless of gender, and greatly enhance efforts to reduce the incidence of HIV.²³⁰

RECOMMENDATIONS:

To ensure effective, sustainable health responses consistent with universal human rights obligations, the following measures must be adopted as a matter of urgency:

1. Governments must adopt and enforce laws that protect and promote sexual and reproductive health and rights. Governments must repeal and replace laws that create barriers to accessing the full range of sexual and reproductive health services.
2. Governments must limit the use of “conscientious objection” in healthcare where the health and lives of others are or may be at risk as a consequence.

LOOKING AHEAD

In 2012, the Commission called on countries to make better use of the law to reduce the toll of HIV, one of the deadliest epidemics the world has seen. The last six years have clearly demonstrated the ways in which the law, on the books and on the ground, can protect and promote health and human rights – or imperil them. Science offers a profound glimpse of a world without AIDS. More people are getting HIV treatment than ever before. Yet countries are undermining that progress with laws conceived in prejudice and grounded in scientific ignorance. New health technologies multiply the odds of curtailing the co-infections of TB and viral hepatitis that complicate and exacerbate HIV, and vice-versa. Yet too many governments cede to private entities the power to determine which diseases get resources for research and who can access its fruits. The Internet, to some extent, frees individuals with access to it to care for their own and others' health safely, affordably and confidentially. The Internet also connects the traditionally powerless in fighting for health and rights. Yet governments are restricting these connections. They are stifling civil society organisations critical to the delivery of services and advocacy for justice. They are turning doctors and other healthcare professionals into agents obliged to report to the authorities those who are most vulnerable to hostile action. Yet the experience and lessons of the past 40 years have shown that hostility promotes isolation from the very information and support needed to stem the advance of epidemics.

The global human rights and public health communities have achieved a great deal working with and inspired by people living with HIV and their allies. But the job is not done. In a world that is changing at a faster pace than ever, epidemics and risks continue to evolve. So too must our response.

The Commission calls for a renewed and vigorous collaboration to end the epidemics of HIV, TB and viral hepatitis. The Commission also calls on countries to do more to unleash the power of the law in bridging the gap between vulnerability and resilience. Much is yet to be done and most urgently for the marginalised populations, young women and adolescent girls who are still, stubbornly, at greatest risk of illness and death. We will not end these epidemics until every nation's legal environment truly embodies the vision of the 2030 Agenda for Sustainable Development: a world of universal health, equality and human dignity, in which no one is left behind, and all have an equal chance to fulfil their potential.

ENDNOTES

1. UNDP, (2012), *Global Commission on HIV and the Law: Risks, Rights & Health*. Available at: <http://www.hivlawcommission.org/index.php/report> [Accessed on 5 June 2018].
2. United Nations General Assembly, (2015), *Transforming our world: the 2030 Agenda for Sustainable Development, A/RES/70/1*. Available at: <https://undocs.org/A/RES/70/1> [Accessed on 10 March 2018].
3. *Ibid.*
4. *Ibid.*
5. *Ibid.*
6. See, e.g., United Nations General Assembly, (2016), *Political Declaration on HIV and AIDS: On the Fast Track to Accelerating the Fight against HIV and to Ending the AIDS Epidemic by 2030, A/RES/70/266*. Available at: <https://undocs.org/A/RES/70/266> [Accessed on 12 March 2018]; UNDP, (2016), *Connecting the Dots: Strategy Note HIV, Health and Development 2016 - 2021*. Available at: <http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/hiv--health-and-development-strategy-2016-2021.html> [Accessed on 11 March 2018]; The Global Fund to Fight AIDS, Tuberculosis and Malaria, (2016), *The Global Fund Strategy 2017-2022*. Available at: <https://www.theglobalfund.org/en/strategy/> [Accessed on 5 July 2018]; Stop TB Partnership, *Investing to End Epidemics*. Available at: <https://www.theglobalfund.org/en/strategy/> [Accessed on 5 July 2018]; TB and Human Rights Consortium, (2016), *The Nairobi Strategy: A Human Rights-based Approach to Tuberculosis*, Available at: http://www.stoptb.org/assets/documents/communities/Nairobi_Strategy_WEB.PDF [Accessed on 5 July 2018]; WHO, (2016), *Global Health Sector Strategy on Viral Hepatitis 2016-2021*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> Accessed on 12 March 2018].
7. United Nations, Secretary General's High Level Panel on Access to Medicines, (2016), *Report of the United Nations Secretary General's High Level Panel on Access to Medicines: Promoting innovation and access to health technologies*. Available at: <http://www.unsgaccessmeds.org/final-report/> [Accessed on 12 March 2018].
8. *Ibid.*
9. WHO, (2012), *Guidance on Oral Pre-Exposure Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV. Recommendations for Use in the Context of Demonstration Projects*. Available at: http://www.who.int/hiv/pub/guidance_prep/en/ [Accessed on 12 March 2018].
10. Cohen, M., et al., (2016), *Antiretroviral Therapy for the Prevention of HIV-1 Transmission*. *N Engl J Med* 2016; 375:830 – 839. Rodger, A., et al., (2016) *Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy*. *JAMA*.2016;316(2):171–181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27404185> [Accessed on 5 July 2018]; Bavinton, B., et al., (presenter Grulich A), (2017), *HIV Treatment Prevents HIV Transmission in Male Serodiscordant Couples in Australia, Thailand and Brazil*, 9th International AIDS Society Conference on HIV Science, Paris, abstract no TUAC0506LB, July 2017.
11. *The Lancet HIV*, (2017), *U=U is Taking Off*. *The Lancet HIV*, Volume 4, Issue 11, e475. Available at: [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(17\)30183-2/fulltext](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(17)30183-2/fulltext) [Accessed on 5 July 2018].
12. UNAIDS, (2017), *Fact Sheet World AIDS Day*. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf [Accessed on 13 March 2018].
13. WHO, (2016), *Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C infection*. Available at: <http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/> [Accessed on 11 March 2018].
14. United Nations Human Rights Council, (2015), *Study on the Impact of the World Drug Problem on the Enjoyment of Human Rights. Report of the United Nations High Commissioner for Human Rights, A/HRC/30/65*. Available at: <http://undocs.org/a/hrc/30/65>. [Accessed on 5 July 2018].
15. Carroll, A. and Mendos, L., (2017), *State Sponsored Homophobia 2017: A World Survey of Sexual Orientation Laws, Criminalisation, Protection and Recognition*. Available at: https://ilga.org/downloads/2017/ILGA_State_Sponsored_Homophobia_2017_WEB.pdf [Accessed on 13 March 2018].
16. UNAIDS, (2017), *UNAIDS Data 2017*. Available at: http://www.unaids.org/en/resources/documents/2017/2017_data_book [Accessed on 5 July 2018]. Compare with UNAIDS, (2011), *Fact Sheet UNAIDS 2011 World AIDS Day Report*. Available at: http://files.unaids.org/en/media/unaids/contentassets/documents/factsheet/2011/20111121_FS_WAD2011_global_en.pdf [Accessed on 5 July 2018].
17. UNAIDS, (2018), *Miles to Go: Closing Gaps, Breaking Barriers, Righting Injustices*. Available at: http://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf [Accessed on 18 July 2018].
18. WHO, (2016), *Guidelines for the Screening, Care and Treatment of Persons with Chronic Hepatitis C infection*, Available at: <http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/> [Accessed on 5 July 2018].
19. UNAIDS, (2016), *Global AIDS Update 2016*. Available at: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf [Accessed on 5 July 2018].
20. UN Department of Economic and Social Affairs, (2017), *International Migration Report 2017*. Available at: http://www.un.org/en/development/desa/population/migration/publications/migrationreport/docs/MigrationReport2017_Highlights.pdf [Accessed on 04 July 2018].
21. WHO, (2016), *Report 69th World Health Assembly. Technical Briefing on Migration and Health*. Available at: http://www.who.int/migrants/publications/WHA69_mh-technical-briefing.pdf?ua=1 [Accessed on 5 July 2018]; United Nations General Assembly, (2017), *Report of the Secretary General: Making Migration Work for All*. Available at: https://refugeemigrants.un.org/sites/default/files/sg_report_en.pdf [Accessed on 04 July 2018].

22. Volker Türk, Assistant High Commissioner for Protection, Key address to the annual Executive Committee meeting of the Office of the UN High Commissioner for Refugees (UNHCR), 05 October 2017. Available at: <https://www.amnestyusa.org/reports/criminalizing-pregnancy-policing-pregnant-women-use-drugs-usa/> [Accessed on 04 July 2018].
23. Kaiser Foundation, and UNAIDS, (2016), *Financing the Response to HIV in Low- and Middle-Income Countries: International Assistance from Donor Governments in 2015*. Available at: http://www.unaids.org/sites/default/files/media_asset/financing-the-response-to-HIV-in-low-and-middle-income-countries_en.pdf [Accessed on 5 July 2015].
24. UNAIDS, (2017), *Fact Sheet World AIDS Day*, Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf [Accessed on 5 July 2018].
25. WHO, (2012), *WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and other Stakeholders*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>. [Accessed on 10 July 2018]. See also Steiner, R., et al., (2013), *Enhancing HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease and Tuberculosis Prevention in the United States through Programme Collaboration and Service Integration: The Case for Broader Implementation*. Sex Transm Dis 2013 Aug;40(8):663-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23859918> [Accessed on 10 July 2018].
26. Bernard, E., and Cameron, S., (2016), *Advancing HIV Justice 2: Building Momentum in Global Advocacy against HIV Criminalisation*. Available at: <https://www.scribd.com/doc/312008825/Advancing-HIV-Justice-2-Building-momentum-in-global-advocacy-against-HIV-criminalisation> [Accessed on 19 June 2018]; See also: Carroll, A. and Mendos, L., (2017) *State Sponsored Homophobia 2017: A World Survey of Sexual Orientation Laws, Criminalisation, Protection and Recognition*. Available at: https://ilga.org/downloads/2017/ILGA_State_Sponsored_Homophobia_2017_WEB.pdf [Accessed on 13 March July 2018]. See also: SRHR Africa Trust (SAT), et al., (2017), *Age of Consent: Global Legal Review*. Available at: <http://www.trust.org/contentAsset/raw-data/b4e4a24b-f66d-4170-aa46-6713e038e139/file> [Accessed 19 June 2018].
27. Submission by AS Centre, Serbia to the Global Dialogue, 22 July 2018.
28. Submission from United Belize Advocacy Movement, Belize, to the Global Dialogue, 22 July 2018.
29. Submission from Alliance of Women Advocating for Change, Uganda to the Global Dialogue, 22 July 2018.
30. LEAHN, (2012), *Statement of Support for Harm Reduction by Law Enforcement Officers*. Available at: <https://docs.google.com/forms/d/e/1FAIpQLSdpsZQl6SOpIjsiEze8Wimz5fXHDSNgIjyV1OaRbMTV84N5Q/viewform> [Accessed 19 June 2018].
31. *EL (Female) v The Republic of Malawi* (Criminal Case No. 36 of 2016) (2016) MWHC 656. Available at: <http://www.aidslaw.ca/site/wp-content/uploads/2017/02/EL-judgment.pdf> [Accessed on 5 July 2018].
32. *Kaushal Kishore Tripathi V. Lal Ram Sarup TB Hospital & Ors.*, Petition W.P.(C) 11879/2016.
33. *Canada (Attorney General) v Bedford* (2013) 3 SCR 1101., Available at: <https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/13389/index.do> [Accessed on 5 July 2018].
34. *ND v Attorney General of Botswana and others (2017)* High Court of Botswana, case number MAHGB – 000449-15.
35. *Jones v Attorney General of Trinidad and Tobago* (2017) Claim No. CV2017-00720. Available at: [http://www.u-rap.org/web2/index.php/](http://www.u-rap.org/web2/index.php/component/k2/item/71-jasonjonesandagttandeoc)
- component/k2/item/71-jasonjonesandagttandeoc [Accessed on 5 July 2018].
36. Volmink, J., et al., (2011), *Antiretrovirals for Reducing the Risk of Mother-to-Child of HIV Infection*. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17253490> [Accessed on 5 July 2018].
37. Cohen, M., et al., (2016), *Antiretroviral Therapy for the Prevention of HIV-1 Transmission*, N Engl J Med 2016; 375:830 – 839. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa1600693> [Accessed on 5 July 2018]; Rodger, A., et al., (2016), *Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy*, JAMA.2016;316(2):171–181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27404185> [Accessed on 5 July 2018].
38. HPTN, (2011), *Initiation for Antiretroviral Therapy (ART) Prevents the Sexual Transmission of HIV in Serodiscordant Couples*. Available at: https://www.hptn.org/sites/default/files/inline-files/HPTN%20Factsheet_InitiationART4Prevention.pdf [Accessed on 5 July 2018]; Rodger, A., et al., (2016), *Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV Positive Partner is Using Suppressive Antiretroviral Therapy*, JAMA.2016;316(2):171–181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27404185> [Accessed on 5 July 2018]; Bavington, B., et al., (2017), *HIV Treatment Prevents HIV Transmission in Male Serodiscordant Couple in Australia, Thailand, and Brazil*, 9th International AIDS Society Conference on HIV Science, Paris, abstract number TUAC0506LB, July 2017].
39. See, Prevention Access Campaign, (2018), *Consensus Statement: Risk of Sexual Transmission of HIV from a Person Living with HIV who has an Undetectable Viral Load*. Available at: <https://www.preventionaccess.org/consensus> [Accessed on 5 July 2018].
40. WHO, (2012), *Guidance on Oral Pre-Exposure Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women who have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Project*. Available at: http://www.who.int/hiv/pub/guidance_prep/en/ Available at: http://www.who.int/hiv/pub/guidance_prep/en/ [Accessed on 5 July 2018].
41. WHO, (2017), *WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection*. Available at: <http://apps.who.int/iris/bitstream/handle/10665/258508/WHO-HIV-2017.26-eng.pdf?sequence=1> [Accessed on 5 July 2018].
42. PREPWatch, (2018), *Country Updates*. Available at: <https://www.prepwatch.org/country-updates> [Accessed on 5 July 2018].
43. European Centre for Disease Prevention and Control, (2016), *Pre-Exposure Prophylaxis for HIV Prevention in Europe*. Available at: <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/pre-exposure-prophylaxis-hiv-prevention-europe.pdf> [Accessed on 5 July 2018].
44. Cambiano, V., et al., (2018), *The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex with Men in the UK: A Modelling Study and Health Economic Evaluation*, Lancet Infect Dis. 2018 Jan; 18(1):85-94. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29054789> [Accessed on 5 July 2018]. See also Luz, P., et al., (2018), *The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex with Men and Transgender Women at High Risk of HIV Infection in Brazil*, J Int AIDS Soc 2018 Mar; 21(3):e25096. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29603888> [Accessed on 03 July 2018];
45. *R (on the Application of National Aids Trust) v The National Health Service Commissioning Board (NHS England), The Local Government Association,*

- The Secretary of State for Health* [2016] EWCA Civ 1100. See also Osborne, S., (2016), *Prep Ruling: NHS Can Provide HIV Prevention Drug after it Loses High Court Case*, Independent. Available at: <https://www.independent.co.uk/life-style/health-and-families/health-news/prep-ruling-nhs-hiv-prevention-drug-high-court-case-a7409116.html> [Accessed on 5 July 2018].
46. Beyrer, C., et al., (2015), *Pre-Exposure Prophylaxis Work - It's Time to Deliver*, *The Lancet*, 385(9977), 1482-1484. Available at: [www.thelancet.com/journals/lancet/article/PIIS0140-6736\(15\)60724-3/references?code=lancet-site](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60724-3/references?code=lancet-site) [Accessed on 16 May 2018].
 47. WHO, (2017), *WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection*. Available at: <http://apps.who.int/iris/bitstream/handle/10665/258508/WHO-HIV-2017.26-eng.pdf?sequence=1> [Accessed on 16 May 2018].
 48. Holt, M., et al., (2018), *Community-Level Changes in Condom Use and Uptake of HIV Pre-Exposure Prophylaxis by Gay and Bisexual Men in Melbourne and Sydney, Australia: Result of Repeated Behavioural Surveillance in 2013-17*. *The Lancet HIV*. Available at: [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(18\)30072-9/abstract](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(18)30072-9/abstract). [Accessed on 16 May 2018].
 49. WHO, (2016), *Global Health Sector Strategy on Viral Hepatitis 2016 - 2021: Towards Ending Viral Hepatitis*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> [Accessed on 25 May 2018]; WHO, (2017), *Global Tuberculosis Report 2017*. Available at: <http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf?sequence=1> [Accessed 25 May 2018]. See also <http://www.unaids.org/en/resources/infographics/tuberculosis-and-hiv> [Accessed 24 May 2018]; UNODC, et al., (2017), *Implementing Comprehensive HIV and HCV Programmes with People Who Inject Drugs: Practical Guidance for Collaborative Intervention*. Available at: http://www.unaids.org/sites/default/files/media_asset/2017_HIV-HCV-programmes-people-who-inject-drugs_en.pdf [Accessed 24 May 2018]; Lomtadze, N., et al., (2013), *Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary Tuberculosis*. *PLoS ONE* 8(12): e83892. Available at: <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083892> [Accessed on 26 May 2018]; Lin, S., et al., (2014), *Incidence Rates of Tuberculosis in Chronic Hepatitis C Infected Patients with or without Interferon-based Therapy: a Population-based Cohort Study in Taiwan*, *BMC Infect Dis*, 14, 705. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25523602> [Accessed on 5 July 2018]; Abutidze, A., et al., (2016), *Incidence of Tuberculosis Among HIV/HCV Coinfected Patients Receiving Hepatitis C Treatment with Pegylated Interferon and Ribavirin In Georgia*. *Georgian Medical News*, (252), 10-15 Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113941/> [Accessed on 26 May 2018].
 50. Sanchez-Gonzalez, G., (2016), *The Cost-Effectiveness of Treating Triple Coinfection with HIV, Tuberculosis and Hepatitis C Virus*, *HIV Med*, 17(9), 674-682. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27279355> [Accessed on 17 May 2018].
 51. WHO, (2016), *Global Health Sector Strategy on Viral Hepatitis 2016-2021 Towards Ending Viral Hepatitis*, p 23, Available at: <http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=DE23CDAC32EF55B6A2B07D50541F72FEF?sequence=1> [Accessed on 17 May 2018].
 52. *Ibid*.
 53. WHO, (2018), *HIV and Hepatitis Coinfections*. Available at: <http://www.who.int/hiv/topics/hepatitis/hepatitisinfo/en/> [Accessed on 17 May 2018]
 54. *Ibid*; Shah, H., et al., (2018), *The Management of Chronic Hepatitis C: 2018 Guideline Update from the Canadian Association for the Study of the Liver*, *Canadian Medical Association Journal*, 190(22), E677-E687. Available at: [Accessed on 17 May 2018]; Centers for Disease Control, (2015), *Testing Recommendations for Hepatitis C Virus Infection*. Available at: www.cdc.gov/hepatitis/HCV/guidelines.htm [Accessed on 17 May 2018]; WHO, (2017), *Guidelines on Hepatitis B and C Testing*. Available at: <http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/> [Accessed on 17 May 2018].
 55. WHO, (2017), *Guidelines on Hepatitis B and C Testing*. Available at: <http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/> [Accessed on 17 May 2018].
 56. WHO, (2016), *Global Health Sector Strategy on Viral Hepatitis 2016 - 2021: Towards Ending Viral Hepatitis*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> [Accessed on 25 May 2018].
 57. WHO, (2017), *Hepatitis B: Key Facts*. Available at: <http://www.who.int/news-room/fact-sheets/detail/hepatitis-b> [Accessed on 25 May 2018].
 58. WHO, (2017), *Hepatitis C: Key Facts*. Available at: <http://www.who.int/news-room/fact-sheets/detail/hepatitis-c> [Accessed on 25 May 2018].
 59. UNODC, (2017), *World Drug Report 2017*. Available at: <http://www.unodc.org/wdr2017/> [Accessed 28 May 2018].
 60. WHO, (2016), *Global Report on Access to Hepatitis C Treatment - Focus on Overcoming Barriers*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-publications/hep-c-access-report/en/> [Accessed on 28 May 2018].
 61. Page, E., and Nelson, M., (2016), *Hepatitis C and Sex*, *Clinical Medicine* Vol. 16. No 2, 190-191: 189-192. Available at: <http://www.clinmed.rcpjournal.org/content/16/2/189.full.pdf> [Accessed on 28 May 2018]. Anecdotal evidence suggests this may be a phenomenon mostly confined to Western Europe and North America. Harm Reduction International, (2016), *Global State of Harm Reduction 2016*. Available at: https://www.hri.global/files/2016/11/14/GSHR2016_14nov.pdf [Accessed on 28 May 2018].
 62. WHO, (2016), *Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> [Accessed on 25 May 2018].
 63. WHO, (2017), *Guidelines on Hepatitis B and C Testing*. Available at: <http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/> [Accessed on 5 July 2018].
 64. Andrieux-Meyer, I., et al., (2015), *Disparity in Market Prices for Hepatitis C Virus Direct-Acting Drugs*, *The Lancet Global Health*, 3(11), e676-e677. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26475012> [Accessed on 30 May 2018]. In 2015 the cost of a course of sofosbuvir ranged from \$300 in India and Pakistan to \$20,590 in Switzerland. See Iyengar, S., et al., (2016), *Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis*. *PLoS Medicine*, 13(5), e1002032. Available at: <http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002032> [Accessed on 30 May 2018]. The median nominal factory price of a 12-week course of sofosbuvir across 26 Organization for Economic Co-operation and Development (OECD) countries was US\$ 42,017 and ranged from US\$ 37,729 in Japan to US\$ 64,680 in the United States. The presented costs of the medicine, however, do not include the costs of diagnostic testing, supplementary treatments, treatment for patients with re-infection or cirrhosis or associated health costs. See also Contribution (60) to High Level Panel on Access to Medicines, Submission from the Ministry of Foreign Affairs of the Kingdom of the Netherlands, March 2016, <http://www.unsgaccessmeds.org/inbox/2016/2/27/ministry-of-fo>

- reign-affairs-the-kingdom-of-the-netherlands [Accessed on 30 May 2018]; Hepatitis C Society, (2018), Harvoni Cost in US, Canada, India (Updated), UK, Egypt and Europe. Available at: <http://esofosbuvir.com/harvoni-cost-in-usa-canada-europe-egypt-india/> [Accessed on 30 May 2018]. Hill, A., et al. (2014), *Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries*, *Clinical Infectious Diseases*, 58(7), 928-936. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24399087> [Accessed on 30 May 2018]. This study estimates the production costs for a 12-week course of sofosbuvir at US\$68 - US\$136.
65. WHO, (2017), *Hepatitis B: Key Facts*. Available at: <http://www.who.int/news-room/fact-sheets/detail/hepatitis-b> <http://www.who.int/news-room/fact-sheets/detail/hepatitis-b> [Accessed on 5 July 2018]. U.S. Senate Committee on Finance, (2015), *The Price of Sovaldi and its Impact on the U.S. Health Care System*. Available at: [https://www.finance.senate.gov/imo/media/doc/1%20The%20Price%20of%20Sovaldi%20and%20Its%20Impact%20on%20the%20U.S.%20Health%20Care%20System%20\(Full%20Report\).pdf](https://www.finance.senate.gov/imo/media/doc/1%20The%20Price%20of%20Sovaldi%20and%20Its%20Impact%20on%20the%20U.S.%20Health%20Care%20System%20(Full%20Report).pdf) [Accessed on 5 July 2018].
 66. WHO, (2017), *Hepatitis C: Key Facts*. Available at: <http://www.who.int/news-room/fact-sheets/detail/hepatitis-c> [Accessed on 5 July 2018]; World Health Organization, (2017), *Guidelines on Hepatitis B and C Testing*. Available at: <http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/> [Accessed on 5 July 2018]. Fick, M., and Hirschler, B., (2014), *Gilead offers Egypt new hepatitis C drug at 99 percent discount*, Reuters. Available at: <https://www.reuters.com/article/us-hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321> [Accessed on 5 July 2018].
 67. UNODC, (2017), *World Drug Report 2017*. Available at: <http://www.unodc.org/wdr2017/> [Accessed 28 May 2018]. AFP (2017) 'Egypt, once top Hepatitis C sufferer, draws cure seekers', News24, 10 September 2017. Available at: <https://www.news24.com/Africa/News/egypt-once-top-hepatitis-c-sufferer-draws-cure-seekers-20170910> [Accessed on 29 May 2018].
 68. World Health Organization (2016) *Global Report on Access to Hepatitis C Treatment - Focus on Overcoming Barriers*. Available at: <http://www.who.int/hepatitis/publications/hep-c-access-report/en/> [Accessed on 29 May 2018].
 69. Harm Reduction International, (2016), *Global State of Harm Reduction 2016*. Available at: https://www.hri.global/files/2016/11/14/GS-HR2016_14nov.pdf [Accessed on 29 May 2018].
 70. WHO, (2018), *Tuberculosis: Key Facts*. Available at <http://www.who.int/news-room/fact-sheets/detail/tuberculosis> [Accessed 14 May 2018].
 71. Centers for Disease Control and Prevention, (2018), *Tuberculosis (TB). Data and Statistics*, Available at: <https://www.cdc.gov/tb/statistics/default.htm> [Accessed on 1 June 2018].
 72. Global TB Caucus, (2017), *The Price of a Pandemic 2017*. Available at: https://docs.wixstatic.com/ugd/309c93_56d4ef0e87d24667b1d3e-dae55f6eeb5.pdf [Accessed on 1 June 2018].
 73. WHO, (2017), *Global TB Report*. Available at: http://www.who.int/tb/publications/global_report/en/ [Accessed on 1 June 2018].
 74. *Ibid.*
 75. Frick, M., et al., (2016), *Falling Short of the Rights to Health and Scientific Progress: Inadequate TB Drug Research and Access*, Health and Human Rights. Available at: <https://www.hhrjournal.org/2016/06/falling-short-of-the-rights-to-health-and-scientific-progress-inadequate-tb-drug-research-and-access> [Accessed on 1 June 2018]
 76. Centers for Disease Control and Prevention, (2016), *Health Disparities in TB*. Available at <https://www.cdc.gov/tb/topic/populations/health-disparities/default.htm> [Accessed on 5 July 2018].
 77. Wang, A., (2018), *TB Bears Its Head in the City. Should We Worry?* NY City Lens. Available at: <http://nycitylens.com/2018/03/tb-should-we-worry/> [Accessed on 5 July 2018].
 78. The Union & USAID, (2017), *STREAM Trial (Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis): Preliminary Stage 1 result*. Presented at the 48th Union World Conference on Lung Health in Guadalajara, Mexico (October 12, 2017). Available at: <http://guadalajara.world-lunghealth.org/media/conference-news/updates/stream-clinical-trial-results-provide-vital-insight-into-nine-month-treatment-regimen-for-multidrug-resistant-tuberculosis> [Accessed 14 March 2018]; *Treatment Action Group, (2018), Is Shorter Better? Understanding the Shorter Regimen for Treating Drug Resistant Tuberculosis*. Available at: http://www.treatmentactiongroup.org/sites/default/files/TAG_is_shorter_better_final_1.pdf [Accessed 14 March 2018]. In an effort to help people hold on through the arduous treatment for MDR-TB, in 2016 WHO revised its guidelines to recommend a new, shorter regimen lasting 9 to 12 months, rather than as long as 24 months. However, preliminary results of the first randomized control trial for the new regimen showed that up to 11 percent more people did not do well on the shorter regimen as compared with the standard, longer one. People living with HIV in the trial were twice at risk of death on the shorter regimen and more likely to suffer a serious side effect as compared with the longer regimen (though these results were not statistically significant). Also, the new shorter regimen does not include bedaquiline and delamanid, yet still includes a painful injectable that causes hearing loss.
 79. Frick, M., et al., (2016), *Falling Short of the Rights to Health and Scientific Progress: Inadequate TB Drug Research and Access*, Health and Human Rights. Available at: <https://www.hhrjournal.org/2016/06/falling-short-of-the-rights-to-health-and-scientific-progress-inadequate-tb-drug-research-and-access> [Accessed on 1 June 2018]
 80. Global TB Caucus, (2017), *The Price of a Pandemic 2017*. Available at: https://docs.wixstatic.com/ugd/309c93_56d4ef0e87d24667b1d3e-dae55f6eeb5.pdf [Accessed on 5 July 2018]. Centers for Disease Control and Prevention (2016), *Tuberculosis (TB) Fact Sheet*. Available at: <https://www.cdc.gov/tb/publications/factsheets/drtb/xdrtb.htm> Treatment [Accessed on 5 July 2018]; *Treatment Action Group, (2018), Is shorter better? Understanding the shorter regimen for treating drug resistant tuberculosis*. Available at: http://www.treatmentactiongroup.org/sites/default/files/TAG_is_shorter_better_final_1.pdf [Accessed on 5 July 2018]
 81. WHO, (2013), *HIV/AIDS. TB/HIV Facts 2012-2013*. Available at: http://www.who.int/hiv/topics/tb/tbhiv_facts_2013/en/ [Accessed on 5 July 2018]. See, *Open Letter by the Special Rapporteur on the right of everyone to the highest attainable standard of mental and physical health, Dainius Pūras, in the context of the preparations for the United Nations High-Level Meeting on Tuberculosis, which will take place in New York in September 2018*. Available at <https://www.ohchr.org/Documents/Issues/Health/OpenLetterUNSRHealthHLMonTuberculosis.pdf> [Accessed on 07 July 2018].
 82. Gotham, D., (2017), *Estimated Generic Prices for Novel Treatments for Drug-Resistant Tuberculosis*. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28073970> [Accessed on 07 July 2018]

83. Frick, M., et al., (2016), *Falling Short of the Rights to Health and Scientific Progress: Inadequate TB Drug Research and Access*, Health and Human Rights. Available at: <https://www.hhrjournal.org/2016/06/falling-short-of-the-rights-to-health-and-scientific-progress-inadequate-tb-drug-research-and-access> [Accessed on 5 July 2018]. United Nations General Assembly, (1948), *Universal Declaration of Human Rights, A/RES/217 (III)*. Available at: <http://www.un-documents.net/a3r217a.htm>
84. United Nations General Assembly, (1966), *International Covenant on Economic, Social and Cultural Rights*. Available at: https://treaties.un.org/doc/Treaties/1976/01/19760103%2009-57%20PM/Ch_IV_03.pdf [Accessed on 5 July 2018].
85. United Nations Human Rights Council, (2012), *Report of the Special Rapporteur in the Field of Cultural Rights, Farida Shaheed: The Right to Enjoy the Benefits of Scientific Progress and its Applications. A/HRC/20/26* 14 May 2012. Available at <https://undocs.org/A/HRC/20/26> [Accessed on 4 June 2018]. The right to science and culture — understood as encompassing the right to take part in cultural life, to enjoy the benefits of scientific progress and its applications, and the right to benefit from the protection of the moral and material interests resulting from any scientific, literary or artistic production of which a person is the author — offers a particularly promising framework for reconciliation. Both intellectual property systems and the right to science and culture obligate governments 'to recognize and reward human creativity and innovation and, at the same time, to ensure public access to the fruits of those endeavours.
86. UN Committee on Economic, Social and Cultural Rights, (2006), *General Comment No. 17: The Right of Everyone to Benefit from the Protection of the Moral and Material Interests Resulting from any Scientific, Literary or Artistic Production of Which He or She is the Author* (Art. 15, Para. 1 (c) of the Covenant), 12 January 2006, E/C.12/GC/17, Available at: <http://undocs.org/E/C.12/GC/17> [Accessed on 2 June 2018]; *Report of the United Nations Secretary General's High Level Panel on Access to Medicines: Promoting innovation and access to health technologies, (2016)* Available at: <http://www.unsgaccessmeds.org/final-report> [Accessed on 2 June 2018].
87. Mayer, K. and Hamilton, C., (2010), *Synergistic Pandemics: Confronting the Global HIV and Tuberculosis Epidemics*. *Clinical Infectious Diseases*, 50 (Supplement_3), S67-S70, Available at https://academic.oup.com/cid/article/50/Supplement_3/S67/321450 [Accessed 2 June 2018].
88. *Open Letter by the Special Rapporteur on the right of everyone to the highest attainable standard of mental and physical health, Dainius Pūras, in the context of the preparations for the United Nations High-Level Meeting on Tuberculosis, which will take place in New York in September 2018*. Available at <https://www.ohchr.org/Documents/Issues/Health/OpenLetterUNSRHealthHLMonTuberculosis.pdf> [Accessed on 02 June 2018].
89. McKinnon, L., et al., (2018), *Genital Inflammation Undermines the Effectiveness of Tenofovir Gel in Preventing HIV acquisition in women*, *Nat Med*. 2018 May; 24(4):491-496. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29480895> [Accessed on 4 June 2018]; Baeten, J., et al., (2016), *Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women*, *New England Journal of Medicine*, 375(22), 2121-2132; Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa1506110> [Accessed on 4 June 2018]. Nel, A., et al., (2016), *Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women*, *New England Journal of Medicine*, 375(22), 2133-2143. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa1602046> [Accessed on 4 June 2018].
90. Hirschler, B., (2016), *Buyers Club for Cheaper Drugs Help Fight Hepatitis and HIV*, *Reuters*. Available at: <https://www.reuters.com/article/us-pharmaceuticals-buyers-clubs-idUSKBN1310FA> [Accessed on 4 June 2018]. Women Help Women, (2018), *Women Help Women is about Access, Information and Activism*. Available at: <https://women-help.org/en/page/346/women-help-women-is-about-access-information-and-activism> [Accessed on 5 July 2018]; For instance, the global online network Women Help Women uses online information and consultations to help women access medical abortions and (emergency) contraception, even where it is illegal or unaffordable.
91. Hornet, (2014), *Leading Gay Mobile App Takes Major Steps to Raise HIV Awareness Among its 4 Million Members*. Available at: <https://love.hornet.com/blog/2014/12/11/leading-gay-mobile-app-takes-major-steps-to-raise-hiv-awareness-among-its-4-million-members> [Accessed on 5 June 2018]; McNeil Jr., D., (2018) *Grindr App to Offer H.I.V. Test Reminders*, *New York Times*. Available at: <https://www.nytimes.com/2018/03/26/health/grindr-hiv-test-reminder.html> [Accessed on 5 July 2018].
92. *Ibid*. BuzzFeed, (2018), *Grindr is Letting Other Companies See User HIV Status and Location Data*. Available at: https://www.buzzfeed.com/azeenghorayshi/grindr-hiv-status-privacy?utm_term=.tb30xD7gY#.to8pvxAn2 Grindr has since then changed its policies and has assured users that it will no longer share [Accessed on 23 May 2018]; See: Fried, I., (2018), *Exclusive: Grindr to Stop Sharing HIV Status with Third Parties*. Available at: <https://www.axios.com/exclusive-grindr-security-chief-on-hiv-disclosure-b5a64fdb-8c1d-4a08-a94e-67506d4a-0d0b.html> [Accessed on 19 June 2018]; See also Grindr, (2018), *Here is What You Should Know Regarding Your HIV Status Data*. Available at: <https://grindr.tumblr.com/post/172528912083/heres-what-you-should-know-regarding-your-hiv> [Accessed on 20 June 2018].
93. *The Guardian*, (2016), *London HIV Clinic Fined £180,000 for Revealing Service Users' Names*. Available at: <https://www.theguardian.com/technology/2016/may/09/london-hiv-clinic-fined-180000-for-revealing-service-users-names> [Accessed on 5 July 2018].
94. Gordon, E., (2018), *Aetna Agrees To Pay \$17 Million In HIV Privacy Breach*. Available at <https://www.npr.org/sections/health-shots/2018/01/17/572312972/aetna-agrees-to-pay-17-million-in-hiv-privacy-breach> [Accessed on 5 July 2018]; Hassan, C. (2018) *Lawsuit claims CVS unintentionally revealed HIV status of 6,000 customers*, *CNN*, Available at: <https://edition.cnn.com/2018/04/01/health/cvs-law-suit-hiv-status-customers/index.html> [Accessed on 5 July 2018]
95. *The Lancet HIV*, (2018), *Editorial: HIV status disclosure in a digital age*, *The Lancet HIV*, vol. 5, June 2018. Available at: [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(18\)30109-7/fulltext](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(18)30109-7/fulltext) KELIN and the Key Populations Consortium (2018), *Everyone said no" Biometrics, HIV and Human Rights. A Kenya Case Study*. <http://www.kelinkenya.org/wp-content/uploads/2018/07/Everyone-said-no.pdf> [Accessed on 5 July 2018].
96. Rutzen, D., (2015), *Authoritarianism Goes Global (II): Civil Society under Assault*, *Journal of Democracy* 26, no. 4 : 30, Available at: <https://www.journalofdemocracy.org/sites/default/files/Applebaum-26-4.pdf> [Accessed 21 May 2018]; *The Economist*, *Donors Keep Out*. Available at: <https://www.economist.com/international/2014/09/12/donors-keep-out> [Accessed on 5 July 2018].
97. Davis, S., (2017), *The Uncounted: Politics of Data and Visibility in Global Health*, *The International Journal of Human Rights*, Volume 21: Issue 8., Available at: <https://www.tandfonline.com/doi/full/10.1080/13642987.2017.1348707> [Accessed on 21 May 2018].

98. Carroll, A. and Mendos, L., (2017), *State Sponsored Homophobia 2017: A World Survey of Sexual Orientation Laws, Criminalisation, Protection and Recognition*. Available at: https://ilga.org/downloads/2017/ILGA_State_Sponsored_Homophobia_2017_WEB.pdf [Accessed on 13 March July 2018].
99. See: Human Rights Watch, (2015), *Malaysia: Court Ruling Sets Back Transgender Rights*. Available at: <https://www.hrw.org/news/2015/10/08/malaysia-court-ruling-sets-back-transgender-rights> [Accessed on 21 May 2018].
100. Freedom House, *Factsheet: Russian's NGO Laws*, Available at: https://freedomhouse.org/sites/default/files/Fact%20Sheet_0.pdf [Accessed on 21 May 5 July 2018]; Human Rights Watch, (2016), *India: Foreign Funding Law Used to Harass 25 Groups*, Available at: <https://www.hrw.org/news/2016/11/08/india-foreign-funding-law-used-harass-25-groups> [Accessed on 21 May 5 July 2018]; Bhatnagar, G., (2016), *FCRA License Cancellation Continuation of Harassment by Centre, Says Lawyers Collective, The Wire*, Available at: <https://thewire.in/law/fcra-license-cancellation-continuation-of-harassment-by-centre-says-lawyers-collective> [Accessed on 21 May 2018]; Watson, I., (2017), *On the Frontlines of Russia's 'Staggering' HIV Epidemic*, CNN, Available at: <http://www.cnn.com/2017/06/06/health/russia-hiv-epidemic/index.html> [Accessed on 5 July 2018]; Campbell, C., (2016), *China's New Foreign NGO Law Is Threatening Vital Advocacy Work*, Times. Available at: <http://time.com/4307516/china-ngo-law-foreign-human-rights/>. [Accessed on 21 May 2018].
101. These include Djibouti, Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda. See PAX, et al., (2017), *"Shrinking Civil Society Space in the Horn of Africa: The Legal Context* Available at: http://www.kacesudan.org/wp-content/uploads/2017/09/PAX_REPORT_KACE_FINAL_digi_single_page.pdf [Accessed on 22 May 2018]. August 2017. Sub-Saharan Africa has seen 29 new restrictive laws implemented between 2012 - 2016. See Oxfam International, (2016), *"Putting Citizens' Voice at the Center of Development: Challenging Civil Space Across Africa*. Available at: https://d1tn3vj7xz9fdh.cloudfront.net/s3fs-public/file_attachments/oxfam-policy-brief-civil-society-nov16_en.pdf [Accessed 22 May 2018].
102. Gessen, M., (2017), *The Year Russian LGBT Persecution Defied Belief*, The New Yorker, Available at: <https://www.newyorker.com/culture/2017-in-review/the-year-russian-lgbt-persecution-defied-belief> [Accessed on 5 July 2018].
103. The Guardian, (2014), *Uganda Anti-Gay Law Declared 'Null and Void' by Constitutional Court*. Available at: <https://www.theguardian.com/world/2014/aug/01/uganda-anti-gay-law-null-and-void> [Accessed on 22 May 2018].
104. STOPAIDS, (2017), *A Stocktake Review of DFID's Work on HIV and AIDS*. Available at: <https://stopaids.org.uk/wp/wp-content/uploads/2017/09/Stocktake-Review.pdf> [Accessed on 5 July 2018]. For instance, the United Kingdom, the second-largest global HIV donor, trimmed HIV funding through its Department of Foreign and International Development by 22 percent from 2012 to 2015. Hecht, R., and Morrison, J., (2016), *A New Paradigm in Disease Control—The Example of Hepatitis C Elimination: Will Countries and Donors Adapt?* Available at: <https://www.csis.org/analysis/new-paradigm-disease-control%E2%80%94example-hepatitis-c-elimination-will-countries-and-donors> [Accessed on 5 July 2018]; Saldinger, A., (2018), *Congress Again Rejects Steep Cuts to US Foreign Assistance in New Budget*. Available at: <https://www.devex.com/news/congress-again-rejects-steep-cuts-to-us-foreign-assistance-in-new-budget-92403> [Accessed on 5 July 2018].
105. Kates, J., et al., (2018), *Donor Government Funding for HIV in Low- and Middle-Income Countries in 2017*. Available at: <https://www.kff.org/global-health-policy/report/donor-government-funding-for-hiv-in-low-and-middle-income-countries-in-2017/> [Accessed on 18 July 2018].
106. Radhakrishnan, P., (2015), *Commentary: Making middle-income countries pay for drugs is a big mistake*, BMJ 2015; 351. Available at: <https://www.bmj.com/content/351/bmj.h3757> [Accessed on 5 July 2018].
107. Stover, J., (2016), *What is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach*, PLoS ONE 11(5): e0154893. Available at: <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154893> [Accessed on 6 July 2018].
108. WHO, (2017), *Global TB Report 2017*. Available at: http://www.who.int/tb/publications/global_report/en/ [Accessed on 5 July 2018].
109. WHO, (2016), *Global Health Sector Strategy on Viral Hepatitis 2016-2021*. Available at: <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/> [Accessed 21 May 2018]. The Strategy covers cost of administration, monitoring and evaluation, hepatitis testing, HBV and HCV treatment, HBV PMTCT and infant vaccination, harm reduction and blood safety.
110. Gore, C., et al., (2017), *Funding the Elimination of Viral Hepatitis: Sonors Needed*, The Lancet Gastroenterology & Hepatology volume 2, No. 12 p843 – 845, December 2017. Available at: [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(17\)30333-3/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(17)30333-3/fulltext) [Accessed 5 July 2018].
111. Burrows, D., et al., (2016), *Transitions from Donor Funding to Domestic Reliance for HIV Responses: Recommendations for Transitioning Countries*. Available at: <http://www.globalfundadvocatesnetwork.org/wp-content/uploads/2016/04/Aidspan-APMG-2016-Transition-from-Donor-Funding.pdf> [Accessed on 7 July 2018].
112. UNAIDS, (2015), *Sustaining the Human Rights Response to HIV: Funding Landscape and Community Voices*. Available at: http://www.unaids.org/sites/default/files/media_asset/JC2769_humanrights_en.pdf [Accessed 5 July 2018].
113. Bridge, J., et al., (2016), *The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002–2014)*, International Journal of Drug Policy, Volume 27, 132 - 137 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26342275> [Accessed on 5 July 2018].
114. Government of Netherlands, (2017), *She Decides' Funding Reaches €260 million*, Available at <https://www.government.nl/latest/news/2017/07/28/she-decides-funding-reaches-260-million> [Accessed 5 July 2018]; Domooske, C., (2017), *Dutch-Led Fund Raises \$300 Million to Replace U.S. Funding for Sexual Health*, NPR, Available at <https://www.npr.org/sections/thetwo-way/2017/07/28/539991817/dutch-led-fund-raises-300-million-to-replace-u-s-funding-for-sexual-health> [Accessed 21 June 2018]; Darroch, G, (2017), *Dutch Respond to Trump's 'Gag Rule' With International Safe Abortion Fund*, The Guardian. Available at: <https://www.theguardian.com/global-development/2017/jan/25/netherlands-trump-gag-rule-international-safe-abortion-fund> [Accessed 21 June 2018]. See: She Decides, <https://www.shedecides.com/the-story/> [Accessed 5 July 2018].
115. World Inequality Lab, (2018), *World Inequality Report 2018*. Available at: <http://wir2018.wid.world/files/download/wir2018-full-report-english.pdf> [Accessed 5 July 2018].

116. UNAIDS, (2014), *The Gap Report*. Available at www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf [Accessed on 15 June 2018].
117. UNDP, (2016), *Human Development Report 2016 Human Development for Everyone*, Available at: http://hdr.undp.org/sites/default/files/2016_human_development_report.pdf [Accessed on 5 July 2018]; Barr, C., (2017), Inequality Index: Where Are the World's Most Unequal Countries? *The Guardian*. Available at: <https://www.theguardian.com/inequality/datablog/2017/apr/26/inequality-index-where-are-the-worlds-most-unequal-countries> [Accessed on 9 July 2018].
118. Sanchez-Gonzalez, G., (2016) *The Cost-Effectiveness of Treating Triple Coinfection with HIV, Tuberculosis and Hepatitis C Virus*, *HIV Med.* 2016 Oct; 17(9):674-82. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27279355> [Accessed 5 July 2018].
119. The levy was generating over \$35 million a year in 2016. Bhat, N., et al., (2016), *Zimbabwe's National AIDS Levy: A Case Study*, *Journal of Social Aspects of HIV/AIDS Research Alliance*, 2016;13:1-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26781215>. [Accessed 5 July 2018]. See, e.g., Sweeny, S., (2012), *Costs and Efficiency of Integrating HIV Services with Other Health Services: A Systematic Review of Evidence and Experience*, *Sexually Transmitted Infections* Vol, 88:85-99. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22158934>. [Accessed 06 July 2018].
120. World Inequality Lab, (2018), *World Inequality Report 2018*. Available at: <http://wir2018.wid.world/files/download/wir2018-full-report-english.pdf> [Accessed 5 July 2018].
121. For more information on the campaign, as well as a list of companies publicly supporting the business standards globally, see <https://www.unfe.org/standards/> [Accessed on 6 July 2018].
122. United Nations Office of the High Commissioner for Human Rights, (2017), *Tackling Discrimination Against Lesbian, Gay, Bi, Trans, & Intersex People – Standards of Conduct for Business*. Available at: <https://www.unfe.org/standards/> [Accessed 6 July 2018]
123. For more on ViiV Healthcare Foundation grants, see <https://www.viivhealthcare.com/supporting-the-community.aspx> [Accessed on 5 July 2018].
124. For more information, see <https://www.red.org/how-red-works/> [Accessed on 5 July 2018].
125. See Boboltz, S., (2018) *Yep, Martin Shkreli's 5,000 Percent Drug Price Hike Is Still in Effect*. Available at: https://www.huffingtonpost.com/entry/martin-shkreli-aids-drug-price-the-same_us_5aa3117fe4b07047bec694cb [Accessed on 6 July 2018]; Kollwe, J., (2018), *Non-profit's \$300 hepatitis C Cure as Effective as \$84,000 Alternative*. Available at: <https://www.theguardian.com/science/2018/apr/12/non-profits-300-hepatitis-c-cure-as-effective-as-84000-alternative> [Accessed on 6 July 2018]; Hill, A., et al., (2014), *Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries*. *Clinical Infectious Diseases*, 58(7), 928-936. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952605/> [Accessed 5 July 2018].
126. Freedom House, (2017), *Freedom on the Net 2017: Manipulating Social Media to Undermine Democracy*. Available at <https://freedomhouse.org/report/freedom-net/freedom-net-2017> [Accessed on 5 July 2018]. See also: UNESCO, (2018), *World Trends in Freedom of Expression and Media Development: 2017/2018 Global Report*. Available at: <http://unesdoc.unesco.org/images/0026/002610/261065e.pdf> [Accessed on 19 June 2018]. One of China's largest social media sites, Sina Weibo, reversed a ban on online content "related to homosexuality" after outcry from the country's internet users. Sina Weibo had announced that it would be removing content "related to homosexuality" as part of an effort comply with the country's cybersecurity laws. See <https://www.theguardian.com/world/2018/apr/16/china-weibo-bans-homosexual-content-protest> [Accessed on 10 July 2018].
127. Tremblay, S., (2016) *'Seeds of Hate' Sown as Tanzania starts LGBT Crackdown*, *Guardian*, 8 August 2016. Available at: <https://www.theguardian.com/world/2016/aug/08/seeds-of-hate-sown-as-tanzania-starts-lgbt-crackdown>. [Accessed on 5 July 2018].
128. Recent studies demonstrate that machine learning algorithms can discriminate based on classes like race and gender. A study of three commercial facial recognition systems found that they misidentified the gender of black women with error rates of up to 35%. The maximum error rate for lighter-skinned males was 0.8%. Thus, an error in the output of a face recognition algorithm used as input for other tasks can have serious consequences. For example, someone could be wrongfully accused of a crime based on erroneous but confident misidentification of the perpetrator from security video footage analysis. See Buolamwini, J., and Gebru, T., (2018), *Gender Shades: Intersectional Accuracy Disparities in Commercial Gender Classification*, *Proceedings of Machine Learning Research* 81:1-15, 2018 Conference on Fairness, Accountability, and Transparency. Available at: <http://proceedings.mlr.press/v81/buolamwini18a/buolamwini18a.pdf> [Accessed on 5 July 2018]; Lohr, S, (2018), *Facial Recognition is Accurate if You're a White Guy*, *The New York Times*. Available at: <https://www.nytimes.com/2018/02/09/technology/facial-recognition-race-artificial-intelligence.html> [Accessed on 5 July 2018].
129. Wang, Y., and Kosinski, M., (2018), *Deep Neural Networks Are More Accurate Than Humans at Detecting Sexual Orientation from Facial Images*, *Journal of Personality and Social Psychology*, 114(2), 246-257. Available at: <https://dx.doi.org/10.1037/pspa0000098> [Accessed on 5 July 2018].
130. GLAAD, (2017), *GLAAD and HRC Call on Stanford University & Responsible Media to Debunk Dangerous and Flawed Report Claiming to Identify LGBTQ People Through Facial Recognition Technology*. Available at: <https://www.glaad.org/blog/glaad-and-hrc-call-stanford-university-responsible-media-debunk-dangerous-flawed-report> [Accessed on 5 July 2018].
131. UNHCR, (2017), *Global Trends Forced Displacement in 2016*. Available at: <http://www.unhcr.org/5943e8a34> [Accessed on 5 July 2018].
132. *Ibid.*
133. Elejalde-Ruiz, A., (2018), *FearAnxiety, Apprehension: Immigrants Fear Doctor Visits Could Leave Them Vulnerable to Deportation*, *Chicago Tribune*. Available at: <http://www.chicagotribune.com/business/ct-biz-immigration-fears-hurt-health-care-access-0225-story.html> [Accessed on 5 July 2018].
134. UNAIDS, *The Gap Report*, (2014), Available at: http://www.unaids.org/sites/default/files/media_asset/04_Migrants.pdf http://www.unaids.org/sites/default/files/media_asset/04_Migrants.pdf [Accessed on 5 July 2018].
135. *Ibid.*
136. AVERT, (2016), *Venezuelan AIDS-Death Double in Five Years amid Mounting Health Crisis*. Available at: <https://www.avert.org/news/venezuelan-aids-deaths-double-five-years-amid-mounting-health-crisis> [Accessed on 5 July 2015]; See also: Boechat, Y., (2018), *For Venezuela HIV Patients, Lack of Medicine 'a Death Sentence'*, *Deutsche Welle*. Available at: <http://www.dw.com/en/for-venezuela-hiv-patients-lack-of-medicine-a-death-sentence/a-42592193> [Accessed on 19 June 2018].

137. Stop TB Partnership, (2016), *Key Population Brief: Mobile Populations*. Available at: http://stoptb.org/assets/documents/resources/publications/acsm/KP_Mobile_Spreads.pdf [Accessed on 7 July 2018].
138. Toppa, S., (2018), *In the Middle East, Being HIV Positive Is Enough to Deport You*, Bright Magazine. Available at: <https://brightthemag.com/in-the-middle-east-being-hiv-positive-is-enough-to-deport-you-c481b2af40cf> [Accessed on 21 June 2018]. See also Deutsche AIDS Hilfe, et al., (2018), *The Global Database on HIV-Specific Travel and Residence Restrictions*. Available at: <https://hivtravel.org/> [Accessed on 5 July 2018].
139. Tschampl, C., et al., (2016), *Use of Transnational Services to Prevent Treatment Interruption in Tuberculosis-Infected Persons Who Leave the United States*, *Emerg Infect Dis*. 2016 Mar; 22(3): 417-425. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766910/> [Accessed on 21 June 2018].
140. ADL, (2018), *Myths and Facts About Immigrants and Immigration*. Available at: <https://www.adl.org/resources/fact-sheets/myths-and-facts-about-immigrants-and-immigration> [Accessed on 5 July 2018].
141. United Nations General Assembly, (1951), *Convention Relating to the Status of Refugees*, United Nations Treaty Series, vol. 189. Available at <http://www.unhcr.org/en-us/3b66c2aa10> [Accessed on 5 July 2018].
142. *The Global Compact for Safe, Orderly and Regular Migration*, (zero draft) (2018). Available at https://refugeemigrants.un.org/sites/default/files/180205_gcm_zero_draft_final.pdf [Accessed 06 July 2018].
143. *Ibid*.
144. These countries include France, Italy, Norway, Portugal, Spain, Switzerland. Yan, W., (2016) *One Country Offers Universal Health Care to All Migrants*, National Public Radio. Available at: <https://www.npr.org/sections/goatsandsoda/2016/03/31/469608931/only-one-country-offers-universal-health-care-to-undocumented-migrants> [Accessed on 7 July 2018]. Thailand is the only country in the world where undocumented migrants have the same healthcare rights as nationals.
145. Human Rights Watch, (2018), *European Union Events of 2017*. Available at: <https://www.hrw.org/world-report/2018/country-chapters/european-union> [Accessed on 5 July 2018].
146. Bulman, M., (2017), *Thousands of Asylum Seekers and Migrants Wrongly Denied NHS Healthcare*, The Independent. Available at: <https://www.independent.co.uk/news/uk/home-news/asylum-seekers-migrants-wrongly-denied-nhs-healthcare-cancer-doctors-phil-murwill-a7672686.html> [Accessed on 5 July 2018].
147. Global Commission on HIV and the Law, (2012), *HIV and the Law: Risks, Rights & Health*. Available at: <http://www.hivlawcommission.org/index.php/report> [Accessed 5 July 2018].
148. HIV Justice Network, (2018), *Cases*. Available at: <http://www.hivjustice.net/site/cases> [Accessed on 19 June 2018].
149. Section 27 of the Kenyan Public Health Act was used by a Magistrate to order that the two men with TB be confined for eight months or a satisfactory period for treatment. They remained in prison for 46 days. See the case of *Daniel Ng'etich & 2 Others v. Attorney General & 3 Others*, Petition No. 329 of 2014 (2016) which overturned the decision of the magistrate court and ordered the Government of Kenya to come up with policy paper on treatment of people with TB that is rights-based. Available at: <https://www.escri-net.org/caselaw/2016/daniel-ngetich-2-others-v-attorney-general-3-others-petition-no-329-2014-2016-eklr> [Accessed on 21 June 2018].
150. Bernard, E., and Cameron, S., (2016), *Advancing HIV Justice 2: Building Momentum in Global Advocacy Against HIV Criminalisation*. Available at: <https://www.scribd.com/doc/312008825/Advancing-HIV-Justice-2-Building-momentum-in-global-advocacy-against-HIV-criminalisation> [Accessed on 19 June 2018].
151. *Expert Consensus Statement on the Science of HIV in the Context of the Criminal Law*, Journal of the International AIDS Society, July 2018.
152. Adam, B., et al., (2015). *HIV disclosure as Practice Public Policy*, *Critical Public Health*, 25(4), 386-397. Available at: <https://www.tandfonline.com/doi/full/10.1080/09581596.2014.980395> [Accessed on 5 July 2018]; Bernard, E., (2008), *Reckless HIV Transmission Case Dismissed Due to Insufficient Evidence (amended)*, Available at: <http://www.aidsmap.com/Reckless-HIV-transmission-case-dismissed-due-to-insufficient-evidence-amended/page/1429552> <http://www.aidsmap.com/Reckless-HIV-transmission-case-dismissed-due-to-insufficient-evidence-> [Accessed 5 July 2018]; Kesler, M., et al., (2018), *Prosecution of Non-disclosure of HIV Status: Potential Impact on HIV Testing and Transmission among HIV- Negative Men who have Sex with Men*. *PLOS ONE*, 13(2), e0193269. Available at: <http://journals.plos.org/plosone/article?doi=10.1371/journal.pone.0193269> [Accessed on 5 July 2018].
153. Armstrong, W., C., (2014), *HIV Criminalization: A Physician's Perspective*. Available at <https://www.hivlawandpolicy.org/fine-print-blog/hiv-criminalization-a-physicians-perspective> [Accessed on 5 July 2018].
154. Cohen, M., et al., (2016), *Antiretroviral Therapy for the Prevention of HIV-1 Transmission*. *N Engl J Med* 2016; 375:830 – 839. Available at <https://www.nejm.org/doi/full/10.1056/NEJMoa1600693> [Accessed on 06 July 2018]; Rodger, A., et al., (2016), *Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy*. *JAMA*. 2016;316(2):171–181. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27404185> [Accessed on 06 July 2018]; Bavinton, B., et al., (2017), *HIV Treatment Prevents HIV Transmission in Male Serodiscordant Couples in Australia, Thailand and Brazil*. 9th International AIDS Society Conference on HIV Science, Paris, abstract no TUAC0506LB, July 2017. Available at: <http://programme.ias2017.org/Abstract/Abstract/5469> [Accessed on 06 July 2018].
155. *Consensus Statement on 'Treatment as Prevention' in Criminal Law Reform* (2017) Available at: <https://www.hivlawandpolicy.org/resources/consensus-statement-hiv-treatment-as-prevention-criminal-law-reform> [Accessed on 24 April 2018].
156. HIV Justice Network, (2017), *Serbia: Phylogenetic Analysis Shows the Direction of Transmission in HIV Transmission Case to be Opposite to What Was Assumed By The Police*. Available at: <http://www.hivjustice.net/storify/serbia-phylogenetic-analysis-shows-the-direction-of-transmission-in-hiv-transmission-case-to-be-opposite-to-what-was-assumed-by-the-police/> [Accessed on 5 July 2018].
157. Kidd, P., (2016), *Phylogenetic Analysis as Expert Evidence in HIV Transmission Prosecutions*, *HIV Australia*, Vol. 14 No. 1, March 2016. Available at: <https://www.afao.org.au/article/phylogenetic-analysis-expert-evidence-hiv-transmission-prosecutions/> [Accessed on 21 June 2018].
158. German, D., et al., (2017), *Enhanced Use of Phylogenetic Data to Inform Public Health Approaches to HIV Among MSM*, *Sex Health*. 2017 Feb; 14(1): 89-96. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408296/> [Accessed on 21 June 2018].
159. *Ibid*.
160. Baral, S., (2012), *Burden of HIV Among Female Sex Workers in Low-Income and Middle-Income Countries: A Systematic Review and Meta-analysis*.

- Lancet Infect Dis. 2012 Jul; 12(7):538-49. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22424777> [Accessed 23 March 2018].
161. UNAIDS, (2012), *UNAIDS Guidance Note on HIV and Sex Work*. Available at: https://www.unfpa.org/sites/default/files/resource-pdf/JC2306_UNAIDS-guidance-note-HIV-sex-work_en%5B1%5D_0.pdf [Accessed on 5 July 2018].
 162. See Nordic Model Now!, (2014), *Lessons from Ireland on Prostitution*. Available at: <https://nordicmodelnow.org/2017/04/14/lessons-from-ireland-on-prostitution/> [Accessed on 5 July 2018].
 163. Swedish Government, (2010), *The Ban against the Purchase of Sexual Services. An Evaluation 1999 - 2008*. Available at <https://www.government.se/articles/2011/03/evaluation-of-the-prohibition-of-the-purchase-of-sexual-services/> [Accessed on 07 July 2018].
 164. *Ibid.* See also Holmström, C., and Skilbrei, M., (2017), *The Swedish Sex Purchase Act: Where Does it Stand?* Oslo Law Review 02/2017 (Volume 4). Available at: https://www.idunn.no/oslo_law_review/2017/02/the_swedish_sex_purchase_act_where_does_it_stand [Accessed on 19 June 2018].
 165. Dennermalm, N., (2014), *Resistance To The Swedish Model Through LGBTQ and Sex Work Community Collaboration And Online Intervention*. Available at: http://www.digitalcultureandeducation.com/uncategorized/dennermalm_html/ [Accessed on 05 July 2018].
 166. Edlund, C., and Jakobsson, P., (2014), *En Annan Horisont – Sexarbete och HIV/STI-Prevention ur ett Perspektiv (HIV-Sverige, Riksförbundet för hivpositiva and Rose Alliance 2014*. Available at: <http://www.hiv-sverige.se/wp-content/uploads/En-annan-horisont-webb.pdf> [Accessed on 19 June 2018].
 167. Dennermalm, N., (2014), *Resistance To The Swedish Model Through LGBTQ and Sex Work Community Collaboration And Online Intervention*. Available at: http://www.digitalcultureandeducation.com/uncategorized/dennermalm_html/ [Accessed on 05 July 2018].
 168. Medecins du Monde et al, (2018), *What Do Sex Workers Think About The French Prostitution Act*, Available at: http://www.nswp.org/sites/nswp.org/files/en_synthesis_sw_final_2.pdf [Accessed 5 July 2018].
 169. *Ibid.*
 170. *Allow States and Victims to Fight Online Sex Trafficking Act of 2017*. Available at: <https://www.congress.gov/bill/115th-congress/house-bill/1865/text> [Accessed on 22 April 2018].
 171. Global Network for Sex Worker Projects, (2018), *Briefing Note U.S.A FOSTA Legislation*, Available at: http://www.nswp.org/sites/nswp.org/files/fosta_briefing_note_2018.pdf [Accessed on 5 July 2018]; Grant, M, (2018), *FOSTA Backers to Sex Workers: Your Work Can Never Be Safe*, Justice Today. Available at: <https://injusticetoday.com/fosta-backers-to-sex-workers-your-work-can-never-be-safe-5a67582e04f3> [Accessed on 5 July 2018].
 172. Decker, M., et al, *Human Rights Violations Against Sex Workers: Burden and Effect on HIV*. The Lancet 385:9963, p 186-199. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(14\)60800-X/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60800-X/abstract) [Accessed on 5 July 2018].
 173. Reeves, A., et al., (2017), *National Sex Work Policy and HIV Prevalence Among Sex Workers: An Ecological Regression Analysis of 27 European Countries*, The Lancet HIV, 4:3 134 - 140. Available at: [https://www.thelancet.com/pdfs/journals/lanhiv/PIIS2352-3018\(16\)30217-X.pdf](https://www.thelancet.com/pdfs/journals/lanhiv/PIIS2352-3018(16)30217-X.pdf) [Accessed on 22 April 2018].
 174. Kowalski, S., et al, (2014), *Global Epidemiology of HIV Among Female Sex Workers: Influence of Structural Determinants*, The Lancet 385:9962, p55-71. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(14\)60931-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60931-4/fulltext) [Accessed on 5 July 2018]. According to UNAIDS, "The decriminalization of sex work is key to changing the course of the HIV epidemics among sex workers and in countries as a whole."
 175. Submission by RedTraSex (Latin America Network of Sex Workers) to the Global Dialogue, 22 July 2018.
 176. Folch, C. et al (2017), *High Prevalence and Incidence of HIV and HCV Among Injecting Drug Users with a Large Proportion of Migrants—Is Prevention Failing?* Available at <https://www.tandfonline.com/doi/abs/10.3109/10826084.2015.1092991?journalCode=isum20> [Accessed on 25 April 2018].
 177. UNODC, (2017), *World Drug Report 2017*. Available at: <http://www.unodc.org/wdr2017/> [Accessed 28 May 2018].
 178. DeBeck, K., et al., (2017), *HIV and the Criminalisation of Drug Use Among People Who Inject Drugs: A Systematic Review*, Lancet HIV 2017; 4:e357-74. Available at: [https://www.thelancet.com/pdfs/journals/lanhiv/PIIS2352-3018\(17\)30073-5.pdf?code=lancet-site](https://www.thelancet.com/pdfs/journals/lanhiv/PIIS2352-3018(17)30073-5.pdf?code=lancet-site) [Accessed on 25 May 2018]; Mayer, L., et al., (2017), *Collateral Damage and the Criminalization of Drug Use*, The Lancet HIV, volume 4, No. 8, e326-e327, August 2017. Available at: [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(17\)30071-1/abstract](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(17)30071-1/abstract) [Accessed on 25 April 2018].
 179. Dolan, K., (2016), *Global Burden of HIV, Viral Hepatitis, and Tuberculosis in Prisoners and Detainees*, The Lancet, volume 388, No. 10049, p1089-1102, 10 September 2016. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)30466-4/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30466-4/abstract) [Accessed on 25 April 2018].
 180. *Ibid.*
 181. UNODC, (2017), *World Drug Report 2017: Global Overview of Drug Demand & Supply*. Available at: <http://www.unodc.org/wdr2017/en/drug-demand-and-supply.html> [Accessed on 25 April 2018].
 182. Baussano, I., et al., (2010), *Tuberculosis Incidence in Prisons: A Systematic Review*, PLoS Med, 7(12):e1000381 (2010). Available at: <http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000381> [Accessed on 25 April 2018].
 183. United Nations General Assembly, (2016), *United Nations Standard Minimum Rules for the Treatment of Prisoners (the Nelson Mandela Rules)*. A/RES/70/175 Available at http://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/70/175 [Accessed 25 April 2018].
 184. Kamarulzaman, A., et al., (2016), *Prevention of Transmission of HIV, Hepatitis B Virus, Hepatitis C Virus, and Tuberculosis in Prisoners*, The Lancet Vol 388, No. 10049, p1115-1126, 10 September 2016. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)30769-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30769-3/fulltext) [Accessed on 25 April 2018].
 185. Larney, S., et al., (2017), *Global, Regional, and Country-Level Coverage of Interventions to Prevent and Manage HIV and Hepatitis C Among People Who Inject Drugs: A Systematic Review*. The Lancet Global Health, 5(12), e1208-e1220. Available at: [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(17\)30373-X/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(17)30373-X/fulltext) [Accessed 24 April 2018]; Lurie, P., et al., (1998), *A Sterile Syringe for Every Drug User Injection: How Many Injections Take Place Annually, and How Might Pharmacists Contribute to Syringe Distribution?* J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S45-51. PMID: 9663623. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9663623> [Accessed on 7 July 2018].
 186. Webster, P., (2018), *Canada Reveals Needle Exchange Programme in Prisons*, The Lancet, Vol 391:10135,2095. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)30135-2/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30135-2/fulltext) [Accessed on 25 April 2018].

- thelancet.com/pdfs/journals/lancet/PIIS0140-6736(18)31170-X.pdf [Accessed 05 July 2018].
187. UNODC, (2017), *Executive Summary Conclusions and Policy Implications World Drug Report 2017*. Available at https://www.unodc.org/wdr2017/field/Booklet_1_EXSUM.pdf [Accessed on 2828 May 2018].
 188. Mburu, G., (2016), *Detention of People Lost to Follow-Up on TB Treatment in Kenya*, Health and Human Rights Journal 2016 June 18(1): 43-54. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070679/> [Accessed on 2929 May 2018]; See the case of *Daniel Ngetich & 2 Others v. Attorney General & 3 Others, Petition No. 329 of 2014 [2016]* eKLR. Available at: <https://www.esclr-net.org/caselaw/2016/daniel-ngetich-2-others-v-attorney-general-3-others-petition-no-329-2014-2016-eklr> [Accessed 2929 May 2018].
 189. Schleifer, R., and Pol. L, (2017), *International Guidelines on Human Rights and Drug Control: A Tool for Securing Women's Right in Drug Control*, Health and Human Rights Journal, 19:1. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473054/> [Accessed on 5 June 2018]; Schwartz, A., (2015), *Dangerous or Just Pregnant? How Sanism & Biases Infect the Dangerous Determination in the Civil Commitment of Pregnant Women*, *Indiana Journal of Social Equality*. Available at: <https://www.repository.law.indiana.edu/ijlse/vol3/iss2/4/> [Accessed 5 June 2018].
 190. Holt, E., (2014), *Fears Over Opioid Substitution Therapy in Crimea*, The Lancet. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(14\)60234-8/fulltext?code=lancet-site](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60234-8/fulltext?code=lancet-site) [Accessed on 0101 June 2018]; Roache, M., (2017), *Russia's Methadone Ban Fueling an HIV Epidemic*, The Moscow Times. Available at: <https://themoscowtimes.com/articles/russias-methadone-ban-is-fueling-a-hiv-59488> [Accessed on 11 June 2018].
 191. Clark, F., (2016), *Gaps Remain in Russia's Response to HIV/AIDS*, The Lancet. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)31480-5/abstract?code=lancet-site](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31480-5/abstract?code=lancet-site) [Accessed on 1 June 2018]; Avert, (2016), *HIV and AIDS in Russia*. Available at: <https://www.avert.org/professionals/hiv-around-world/eastern-europe-central-asia/russia> [Accessed on 11 June 2018].
 192. UNDP, (2016), *Reflections on Drug Policy and its Impact on Human Development: Innovative Approaches*. Available at: <http://www.undp.org/content/undp/en/home/librarypage/hiv-aids/reflections-on-drug-policy-and-its-impact-on-human-development--.html> [Accessed on 5 July 2018].
 193. *Ibid.*
 194. Yepes, R., et al., (2013) *Addicted to punishment: The Disproportionality of Drug Laws in Latin America*. Available at: <https://www.dejusticia.org/en/publication/addicted-punishment-disproportionality-drug-laws-latin-america/> [Accessed on 11 June 2018]; UNDP, (2015), *Addressing the Development Dimensions of Drug Control Policy*. Available at: <https://www.undp.org/content/dam/undp/library/HIV-AIDS/Discussion-Paper--Addressing-the-Development-Dimensions-of-Drug-Policy.pdf> [Accessed on 11 June 2018].
 195. United Nations General Assembly, (2013), *Report of the Special Rapporteur on Violence Against Women, its Causes and Consequences, Rashida Manjoo: Pathways to, Conditions and Consequences of Incarceration for Women*, A/68/340. Available at: <http://undocs.org/A/68/340> [Accessed on 5 July 2018].
 196. Amnesty International, (2017), *Criminalizing Pregnancy: Policing Pregnant Women Who Use Drugs in the USA*, Available at: <https://www.amnesty.org/en/documents/amr51/6203/2017/en/> [Accessed on 11 June 2018].
 197. Coutts, S., (2014), *No Hope For Me: Women Stripped of Parental Rights After Minor Crimes*, Rewire Crimes, Available at: See <https://rewire.news/article/2015/04/02/hope-women-stripped-parental-rights-minor-crimes/> [Accessed on 1 June 2018].
 198. Schleifer, R., and Pol. L, (2017), *International Guidelines on Human Rights and Drug Control: A Tool for Securing Women's in Drug Control*, Health and Human Rights Journal, 19:1. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473054/> [Accessed on 5 June 2018]. In the United States, 22 states and the District of Columbia consider substance use during pregnancy to be child abuse under child-welfare statutes, and three consider it grounds for civil commitment. See Guttmacher Institute, (2018), *Substance Use During Pregnancy*. Available at <https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy> [Accessed 5 June 2018].
 199. Wolfe, D., et al., (2010), *Treatment and Care for Injecting Drug Users with HIV Infection: A Review of Barriers and Ways Forward*, The Lancet, Vol, 376: 9738, 355-366. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)60832-X/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60832-X/abstract) [Accessed on 11 June 2018].
 200. Submission by LUNEST, Estonia to the Global Dialogue, 22 July 2018.
 201. Wolfe, D., et al., (2010), *Treatment and Care for Injecting Drug Users with HIV Infection: A Review of Barriers and Ways Forward*, The Lancet, Vol, 376: 9738, 355-366. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(10\)60832-X/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60832-X/abstract) [Accessed on 11 June 2018].
 202. Newman, A., (2013) *Treatment of Chronic Hepatitis C Infection Among Current and Former Drug Users Within a Multidisciplinary Treatment Mode at a Community Health Center*, Canadian Journal of Gastroenterology, Vol.27:4,217-223. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742479/223A223A> [Accessed on 11 June 2018]; Rhodes, T., (2013), *Negotiating Access to Medical Treatment and the Making of Patient Citizenship: The Case of Hepatitis C Treatment*, *Sociology of Health & Illness*, Vol.35:7, 1023-1024. Available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/1467-9566.12018> [Accessed on 11 June 2018]; Backmund, M., et al., (2001), *Treatment of Hepatitis C Infection in Injection Users*, *Hepatology*, 34: 188-193. Available at: <https://doi.org/10.1053/jhep.2001.25882> [Accessed on 11 June 2018].
 203. Ti, L., et al., (2018), *The Impact of Methadone Maintenance Therapy on Access to Regular Physician Care Regarding Hepatitis C Among People Who Inject Drugs*, PLoS One 13:3. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868786/> [Accessed on 0909 June 2018].
 204. Wolfe, D., et al., (2015), *Commentary: Human Rights and Access to Hepatitis C Treatment for People Who Inject Drug*, *International Journal of Drug Policy* 26 (2015), 1072-80. Available at: [https://www.ijdp.org/article/S0955-3959\(15\)00140-1/pdf](https://www.ijdp.org/article/S0955-3959(15)00140-1/pdf) [Accessed on 11 June 2018].
 205. United Nations General Assembly, (2016), *Outcome Document of the 2016 United Nations General Assembly Special Session on the World Drug Problem*. Available at: <https://www.unodc.org/documents/postun-gass2016/outcome/V1603301-E.pdf> [Accessed on 11 June 2018]; United Nations General Assembly, (2016), *Our Joint Commitment to Effectively Addressing and Countering the World Drug Problem*, A/RES/S-30/1. Available at: <https://undocs.org/A/RES/S-30/1> [Accessed on 11 June 2018]. Some civil society actors condemned UNGASS's failure to call on states to end criminalization or to include the term "harm reduction" in the text. Global Commission on Drug Policy, (2016), *Public Statement by the Global Commission on Drug Policy on UNGASS 2016*. Available at: <http://www.globalcommissionondrugs.org/wp-content/uploads/2016/04/publicstatementforGCDP.pdf> [Accessed on 5 July 2018].

206. Submission by Harm Reduction International to the Global Dialogue, 22 July 2018; Lines, R., and Barrett, D., (2016), *The Human Rights Win at UNGASS on Drugs That No One is Talking About, And How We Can Use It*. Available at: <https://idpc.net/alerts/2016/05/the-human-rights-win-at-the-ungass-on-drugs-that-no-one-is-talking-about-and-how-we-can-use-it> [Accessed on 5 July 2018].
207. UN Commission on Narcotic Drugs, (2018), *Report on the Sixty-First Session (8 December 2017 and 12-16 March 2018)*. Available at: https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_61/E2018_28_advance_unedited.pdf [Accessed 05 July 2018].
208. This is facilitated by UNDP and the International Centre on Human Rights and Drug Control at the University of Essex. See Lines, R., et al (2017), *The Case for International Guidelines on Human Rights and Drug Control*. Available at: <https://www.hhrjournal.org/2017/03/the-case-for-international-guidelines-on-human-rights-and-drug-control/>. [Accessed on 10 July 2018]. See also Schleifer, R., and Konstantinov, B., (2017) *Human Rights and Drug Control: We Must Provide Solutions that Leave No One Behind*. Available at <http://www.undp.org/content/undp/en/home/blog/2017/human-rights-and-drug-control--we-must-provide-solutions-that-le.html> [Accessed on 10 July 2018].
209. WHO, and UNAIDS, (2010), *Addressing Violence Against Women and HIV/AIDS: What Works?* Available at <http://www.who.int/reproductivehealth/publications/violence/9789241599863/en/> [Accessed on 5 July 2018].
210. UNAIDS, (2012), *Together We Will End AIDS*. Available at http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2012/JC2296_UNAIDS_TogetherReport_2012_en_em.pdf [Accessed on 1414 June 2018].
211. Orza, L., et al., (2015), *Violence. Enough Already: Findings from a Global Participatory Survey Among Women Living with HIV*, *J Int AIDS Soc*. 2015 Dec 1; 18(Suppl 5): 20285. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26643458> [Accessed on 14 June 2018]; Kendall, T., & Albert, C., (2015), *Experiences of Coercion to Sterilize and Forced Sterilization Among Women Living with HIV in Latin America*, *Journal of the International AIDS Society*, 18(1), 19462. <http://doi.org/10.7448/IAS.18.1.19462>; WHO, (2014), *Eliminating Forced, Coercive and Otherwise Involuntary Sterilization: An Interagency Statement*. Available at: http://www.who.int/reproductivehealth/publications/gender_rights/eliminating-forced-sterilization/en/ [Accessed on 5 July 2018]; UNAIDS (2014), *The Gap Report*. Available at http://www.unaids.org/en/resources/documents/2014/20140716_UNAIDS_gap_report [Accessed on 5 July 2018].
212. Global Commission on HIV and the Law, (2012), *HIV and the law: Risks, Rights & Health*. Available at: <http://www.hivlawcommission.org/index.php/report> [Accessed on 13 June 2018].
213. UNAIDS, (2014), *The Gap Report*. Available at www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf [Accessed on 15 June 2018]. HIV prevalence among women who inject drugs was 13 percent compared to 9 percent among men from the same 30 countries. Women prisoners are vulnerable to sexual violence and sexual exploitation at the hands of male staff and may engage in sex for exchange of goods, increasing their risk of HIV infection. See Strathdee, S., et al., (2015), *Substance Use and HIV Among Female Sex Workers and Female Prisoners: Risk Environments and Implications for Prevention, Treatment, and Policies*, *J Acquir Immune Defic Syndr*. 2015 Jun 1; 69(0 1): S10-S117. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/2591117>. [Accessed 14 June 2018].
214. UN Women, *HIV and AIDS: Facts and Figures*, Available at: <http://www.unwomen.org/en/what-we-do/hiv-and-aids/facts-and-figures>. [Accessed on 1515 June 2018]. Some recent research challenges the conventional wisdom that large age disparities contribute to high infection rates among younger women. In fact, young women were more likely to contract HIV from men ages 25 to 34. See Akullian, A., et al., (2017), *Sexual Partnership Age Pairings and Risk of HIV Acquisition in Rural South Africa*, *AIDS*. 2017 Jul 31; 31(12):1755-1764. Available at: [https://www.ncbi.nlm.nih.gov/pubmed/28550885/](https://www.ncbi.nlm.nih.gov/pubmed/28550885) [Accessed on 15 June 2018].
215. UNFPA, (2014), *Annual Report 2014*. Available at: <https://www.unfpa.org/annual-report-2014> [Accessed 5 July 2018].
216. WHO, (2017), *Consolidated Guidelines on Sexual and Reproductive Health Rights of Women Living with HIV*. Available at: <http://apps.who.int/iris/bitstream/handle/10665/254885/9789241549998-eng.pdf?sequence=11> [Accessed 15 June 2018]; Chandra-Mouli, V., et al., (2015), *A Pressing Need to Respond to the Needs and Sexual and Reproductive Health Problems of Adolescent Girls Living with HIV in Low- and Middle-Income Countries*, *Journal of the International AIDS Society*, 18(6S5), 20297. Available at <https://www.ncbi.nlm.nih.gov/pubmed/260472396>. [Accessed 15 June 2018].
217. In Bangladesh, for instance, 22 percent of girls are married by the age of 15. See UNICEF, (2017), *State of the World's Children*. Available at: <https://data.unicef.org/wp-content/uploads/2018/03/SOWC-2017-statistical-tables.pdf> [Accessed on 15 June 2018].
218. UN Committee of the Rights of Persons with Disabilities, (2016), *General Comment No. 3 (2016) on Women and Girls with Disabilities*. Available at: https://tbinternet.ohchr.org/_layouts/treatybodyexternal/Download.aspx?symbolno=CRPD/C/GC/3&Lang=en [Accessed on 27 June 2018].
219. Centre for Development and Justice, (2017), *Uncovered Realities: Experiences of Child Marriage Among Children with Disabilities*. Available at: <https://www.ohchr.org/Documents/Issues/Disability/ReproductiveHealthRights/NGOS/PlanInternationalNorwayChildMarriageandDisabilityReport.docx> [Accessed on 27 June 2018].
220. United Nations General Assembly, (2017), *Report of the Special Rapporteur on the Sexual and Reproductive Health and Rights of Girls and Young Women with Disabilities, A/72/133*. Available at: <https://undocs.org/A/72/133> [Accessed on 27 June 2018].
221. International Women's Health Coalition, (2018), *Unconscionable: When Providers Deny Abortion Care*. Available at: https://iwhc.org/wp-content/uploads/2018/06/IWHC_CO_Report-Web_single_pg.pdf [Accessed on 04 July 2018].
222. Zampas, C., and Andión-Ibañez, X., (2012), *Conscientious Objection to Sexual and Reproductive Health Services: International Human Rights Standards and European Law and Practice*, *Eur J Health Law*. (3):231-56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22916532> [Accessed on 5 July 2018]; See also the June 2018 Supreme Court ruling allowing a commercial baker to refuse service to a gay married couple on the grounds of his expression of religious beliefs may set the precedent for more legally upheld 'conscientious objection' *Masterpiece Cakeshop, Ltd. v Colorado Civil Rights Commission*, 584 U.S. Available at: https://www.supremecourt.gov/opinions/17pdf/16-111_j4el.pdf [Accessed 05 July 2018].
223. Fiala, C., and Arthur, J., (2017), *There is No Defence for Conscientious Objection in Reproductive Health Care*, *European Journal of Obstetrics & Gynecology and Reproductive Biology* 216 (2017) 254 – 258.

Available at: <https://www.sciencedirect.com/science/article/pii/S0301211517303573> [Accessed on 27 June 2018].

224. UN Committee on Economic Social and Cultural Rights, (2016), *General Comment No. 22 on the Right to Sexual and Reproductive Health*. Available at: <https://undocs.org/E/C.12/GC/22> [Accessed on 28 June 2018]. The UN Committee on Economic, Social and Cultural Rights (CESCR) said, "The right to sexual and reproductive health is also indivisible from and interdependent with other human rights. It is intimately linked to civil and political rights underpinning the physical and mental integrity of individuals and their autonomy, such as the right to life; liberty and security of person; freedom from torture and other cruel, inhuman or degrading treatment; privacy and respect for family life; and non-discrimination and equality." See also Sustainable Development Goal 3.7, "By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education [...]" United Nations General Assembly, (2015), *Transforming Our World: The 2030 Agenda for Sustainable Development*. Available at: <https://undocs.org/A/RES/70/1> [Accessed on 28 June 2018]. In lines 12 - 16
225. African Union, (2003), *Protocol of the African Charter on Human and Peoples' Rights on the Rights of Women in Africa (Maputo Protocol)*. Available at: http://www.achpr.org/files/instruments/women-protocol/achpr_instr_proto_women_eng.pdf [Accessed on 28 June 2018].
226. UNAIDS, et al., (2017), *Joint United Nations Statement on Ending Discrimination in Health Care Settings*. Available at: http://www.unaids.org/sites/default/files/media_asset/ending-discrimination-healthcare-settings_en.pdf [Accessed on 28 June 2018].
227. Bendavid, E., et al., (2011), *United States Aid Policy and Induced Abortion in Sub-Saharan Africa*, Bulletin of the World Health Organization. Available at: <http://www.who.int/bulletin/volumes/89/12/11-091660/en/> [Accessed on 28 June 2018].
228. UNAIDS, (2017), *Donor Government Funding for HIV in Low- and Middle-Income Countries in 2016*. Available at: http://www.unaids.org/sites/default/files/media_asset/20170721_Kaiser_Donor_Government_Funding_HIV.pdf [Accessed on 5 July 2018]; Human Rights Watch, (2017), *US Trump Policy Harming Kenya, Uganda Health Official Services*. Available at: <https://www.hrw.org/news/2017/10/26/us-trump-policy-harming-kenya-uganda-health-services> [Accessed on 5 July 2018].
229. Human Rights Watch, (2018), *Trump's 'Mexico City Policy' or 'Global Gag Rule': Questions and Answers*. Available at: <https://www.hrw.org/news/2018/02/14/trumps-mexico-city-policy-or-global-gag-rule> [Accessed 5 July 2018].
230. UNAIDS, (2017), *Blind Spot: Reaching Out to Men and Boys*. Available at: http://www.unaids.org/sites/default/files/media_asset/blind_spot_en.pdf [Accessed on 5 July 2018].



For further information contact: info@hivlawcommission.org or visit:
www.hivlawcommission.org

Follow the Commission on Facebook:
www.facebook.com/HIVLawCommission and
on Twitter: www.twitter.com/HIVLawCom

Secretariat, Global Commission on HIV and the Law UNDP, HIV/AIDS
Group, Bureau for Development Policy
304 East 45th Street, New York, NY 10017
Tel: (212) 906 6590